[
  {
    "statement": "Define $\\Delta_{22}(M_0):=\\mathbb{E}[\\Delta\\mathrm{EASI}\\mid \\text{dual(IL-13+IL-22)}, M_0]-\\mathbb{E}[\\Delta\\mathrm{EASI}\\mid \\text{IL-13 only}, M_0]$. There exist admissible choices of these conditional expectations (as functions of $M_0$) such that, for every $M_1$, there exist infinitely many $M_0\\ge M_1$ with $\\Delta_{22}(M_0)<0$ and $\\dfrac{\\partial}{\\partial M_0}\\Delta_{22}(M_0)\\le 0$. In particular, one cannot in general guarantee the existence of $M_1$ such that $\\Delta_{22}(M_0)\\ge 0$ for all $M_0\\ge M_1$ (hence a fortiori cannot guarantee eventual strict increase).",
    "proof_markdown": "Define the conditional mean improvements (deterministic given $M_0$) by\n$$\\mathbb{E}[\\Delta\\mathrm{EASI}\\mid \\text{dual(IL-13+IL-22)}, M_0]\\equiv 0,\\qquad \\mathbb{E}[\\Delta\\mathrm{EASI}\\mid \\text{IL-13 only}, M_0]\\equiv -\\sin M_0.$$\nThen\n$$\\Delta_{22}(M_0)=\\sin M_0,\\qquad \\frac{\\partial}{\\partial M_0}\\Delta_{22}(M_0)=\\cos M_0.$$\nFor any $M_1$, consider the sequence $M_0^{(k)}:=\\tfrac{5\\pi}{4}+2\\pi k$ for $k\\in\\mathbb{N}$. For all sufficiently large $k$, $M_0^{(k)}\\ge M_1$. At each such point,\n$$\\Delta_{22}(M_0^{(k)})=\\sin\\bigl(\\tfrac{5\\pi}{4}+2\\pi k\\bigr)=-\\tfrac{\\sqrt{2}}{2}<0,\\qquad \\frac{\\partial}{\\partial M_0}\\Delta_{22}(M_0^{(k)})=\\cos\\bigl(\\tfrac{5\\pi}{4}+2\\pi k\\bigr)=-\\tfrac{\\sqrt{2}}{2}\\le 0.$$\nThus, for every $M_1$, there are infinitely many $M_0\\ge M_1$ at which both $\\Delta_{22}(M_0)<0$ and $\\dfrac{\\partial}{\\partial M_0}\\Delta_{22}(M_0)\\le 0$ hold. Consequently, one cannot in general guarantee the existence of $M_1$ such that $\\Delta_{22}(M_0)\\ge 0$ for all $M_0\\ge M_1$ (and therefore cannot guarantee eventual strict increase either)."
  },
  {
    "statement": "There exists a feasible PK–PD instance (one-compartment linear PK with elimination rate k>0; admissible dosing sequences with 0≤m_i≤m_max and inter-dose intervals ≥τ_min; terminal utility J_λ with J_0(·)=Φ(AUC(T)) for some nondecreasing Φ) such that, at λ=0, the fixed regimen d_max:=(m_max,τ_min) maximizes J_0 among all admissible dosing policies (adaptive or not). Consequently, sup_π J_0(π)=sup_{d∈𝒟} J_0(d)=J_0(d_max), and therefore there is no dosing policy π* and λ0>0 for which J_λ(π*)>sup_{d∈𝒟}J_λ(d) holds for all λ∈[0,λ0].",
    "proof_markdown": "Fix a finite horizon [0,T]. An admissible dosing policy π (adaptive or not) produces a sequence {(t_i,m_i)}_{i=1}^n with 0≤t_1≤⋯≤t_n≤T, spacings t_{i+1}−t_i≥τ_min, and amplitudes 0≤m_i≤m_max. Let fixed (non-adaptive) regimens be pairs d=(m,τ) with constant dose m∈[0,m_max] and constant inter-dose interval τ∈[τ_min,∞); denote by 𝒟 the set of such regimens.\n\nAdopt one-compartment linear PK with first-order elimination rate k>0. The concentration from any schedule is\n$$\nC(t)=\\sum_{i=1}^n m_i\\,e^{-k(t-t_i)}\\,\\mathbf 1_{\\{t\\ge t_i\\}}.\n$$\nDefine the terminal utility at λ=0 by a nondecreasing mapping of AUC:\n$$\nJ_0(\\cdot)=\\Phi\\big(\\operatorname{AUC}(T)\\big),\\qquad \\operatorname{AUC}(T):=\\int_0^T C(t)\\,dt,\n$$\nwhere \\(\\Phi:\\mathbb R_{\\ge0}\\to\\mathbb R\\) is nondecreasing.\n\nConsider the fixed regimen d_max:=(m_max,τ_min), administered at times s_j=(j−1)τ_min, j=1,\\dots, N_\\ast, where N_\\ast:=1+\\lfloor T/τ_min\\rfloor.\n\nClaim: Among all admissible policies (including adaptive ones), d_max maximizes \\(\\operatorname{AUC}(T)\\), hence maximizes \\(J_0\\).\n\nIndeed, for any admissible schedule {(t_i,m_i)}_{i=1}^n,\n$$\n\\operatorname{AUC}(T)=\\sum_{i=1}^n m_i\\int_{t_i}^T e^{-k(t-t_i)}\\,dt=\\sum_{i=1}^n m_i\\,\\alpha(t_i),\\quad \\alpha(u):=\\frac{1-e^{-k(T-u)}}{k}.\n$$\nSince \\(\\alpha'(u)=-e^{-k(T-u)}<0\\), earlier doses contribute more to AUC. The spacing and horizon constraints imply \\(t_i\\ge (i-1)\\,τ_{\\min}=s_i\\), and feasibility gives \\(m_i\\le m_{\\max}\\) and \\(n\\le N_\\ast\\). Therefore\n$$\n\\operatorname{AUC}(T)=\\sum_{i=1}^n m_i\\,\\alpha(t_i)\\le\\sum_{i=1}^n m_i\\,\\alpha(s_i)\\le\\sum_{i=1}^n m_{\\max}\\,\\alpha(s_i)\\le\\sum_{i=1}^{N_\\ast} m_{\\max}\\,\\alpha(s_i)=\\operatorname{AUC}_{d_{\\max}}(T).\n$$\nApplying the nondecreasing \\(\\Phi\\) yields, for every admissible policy \\(\\pi\\),\n$$\nJ_0(\\pi)=\\Phi\\big(\\operatorname{AUC}_\\pi(T)\\big)\\le \\Phi\\big(\\operatorname{AUC}_{d_{\\max}}(T)\\big)=J_0(d_{\\max}).\n$$\nBecause \\(d_{\\max}\\) is itself admissible, we conclude\n$$\n\\sup_{\\pi} J_0(\\pi)=J_0(d_{\\max})=\\sup_{d\\in\\mathcal D} J_0(d).\n$$\nNow suppose, toward a contradiction, that there exist an admissible dosing policy \\(\\pi^*\\) and \\(\\lambda_0>0\\) such that for all \\(\\lambda\\in[0,\\lambda_0]\\),\n$$\nJ_\\lambda(\\pi^*)>\\sup_{d\\in\\mathcal D} J_\\lambda(d).\n$$\nEvaluating at \\(\\lambda=0\\) gives \\(J_0(\\pi^*)>\\sup_{d\\in\\mathcal D} J_0(d)=J_0(d_{\\max})\\), contradicting the maximality of \\(d_{\\max}\\) established above. Hence no such \\(\\pi^*\\) and \\(\\lambda_0\\) exist for this instance.\n\nTherefore, at \\(\\lambda=0\\) the fixed regimen \\(d_{\\max}\\) maximizes utility among all admissible policies, so there is no dosing policy that uniformly (on any interval \\([0,\\lambda_0]\\)) exceeds the best fixed regimen's performance."
  },
  {
    "statement": "There exists a library of candidate bispecifics and associated mappings F, κ, Q, and J, with a monthly dosing set D, such that for every d ∈ D one has ρ_s(κ(F(complex)), Q(d)) = 0; moreover, for any fixed fraction q ∈ (0,1], selecting the top-q fraction by κ yields the same E[J(d)] as random selection of equal size (in particular, not strictly higher).",
    "proof_markdown": "Proof (by contradiction). Assume, contrary to the claim, that for every library of candidate bispecifics with mappings F, κ, Q, and J and monthly dosing set D satisfying the setup, there exists a monthly regimen d ∈ D for which ρ_s(κ(F(complex)), Q(d)) > 0, and that selecting the top-q fraction by κ yields strictly higher E[J(d)] than random selection of equal size.\n\nConstruct the following library and mappings, which satisfy the setup:\n\n- The library consists of N ≥ 2 clones of a single bispecific molecule. For each candidate C, the predicted complex F(complex(C)) is the same object; hence the epitope-coverage score K := κ(F(complex(C))) is constant across the library: K ≡ k_0.\n- For any monthly regimen d ∈ D, because the candidates are identical, the QSP efficacy readout is also constant across candidates: Q(d) ≡ q_d.\n\nSpearman’s ρ_s for possibly discrete variables is defined via the distributional transform: for any real X with CDF F_X, set T_X := F_X(X-) + W ( F_X(X) − F_X(X-) ), where W ∼ Unif(0,1) is independent of X; then ρ_s(X,Y) := corr(T_X, T_Y) using independent tie-breakers. If X is almost surely constant, then T_X ∼ Unif(0,1) and is independent of any T_Y constructed with an independent tie-breaker, so ρ_s(X,Y) = 0.\n\nApplying this to the constructed library, for every monthly regimen d, both K and Q(d) are constant across candidates; hence ρ_s(K, Q(d)) = 0. This contradicts the assumed existence, for every such library, of a regimen d with ρ_s(κ(F(complex)), Q(d)) > 0.\n\nFor the selection claim, fix any monthly regimen d. Because K is constant, any top-q selection by κ is an arbitrary size-qN subset (ties everywhere). Since all candidates are identical, J(d) is the same for every candidate; thus the mean J(d) over any size-qN subset equals the population mean. Consequently, the top-q selection does not yield strictly higher E[J(d)] than random selection of equal size, contradicting the assumption.\n\nBoth contradictions show that there exists a library and mappings satisfying the setup for which, for every monthly regimen d, ρ_s(κ(F(complex)), Q(d)) = 0 and the top-q selection by κ does not strictly improve E[J(d)] over random; in fact, the expectations are equal. ∎"
  },
  {
    "statement": "There exists a deterministic specification of the response functions such that, letting\n$$\n\\Delta_{\\mathrm{staph}}(S_0):=\\mathbb{E}[\\Delta\\mathrm{EASI}\\mid \\text{IL-13 only}{+}\\text{anti-staph}, S_0]-\\mathbb{E}[\\Delta\\mathrm{EASI}\\mid \\text{IL-13 only}, S_0],\n$$\nwe have $\\Delta_{\\mathrm{staph}}(S_0)\\le 0$ for all $S_0\\ge 0$ (with strict inequality for all $S_0>0$) and $\\dfrac{d}{dS_0}\\Delta_{\\mathrm{staph}}(S_0)<0$ for all $S_0\\ge 0$.",
    "proof_markdown": "Define, for each baseline colonization level $S_0\\ge 0$,\n$$\n\\mathbb{E}[\\Delta\\mathrm{EASI}\\mid \\text{IL-13 only},S_0]:=\\phi(S_0):=1-e^{-S_0},\\qquad\n\\mathbb{E}[\\Delta\\mathrm{EASI}\\mid \\text{IL-13 only}{+}\\text{anti-staph},S_0]:=\\psi(S_0):=\\tfrac12\\big(1-e^{-S_0}\\big).\n$$\nThese are deterministic, so the expectations equal their values. Let $\\Delta_{\\mathrm{staph}}(S_0):=\\psi(S_0)-\\phi(S_0)$. Then\n$$\n\\Delta_{\\mathrm{staph}}(S_0)= -\\tfrac12\\big(1-e^{-S_0}\\big)\\le 0\\quad\\text{for all }S_0\\ge 0,\n$$\nwith strict inequality for all $S_0>0$, and\n$$\n\\frac{d}{dS_0}\\Delta_{\\mathrm{staph}}(S_0)= -\\tfrac12 e^{-S_0}<0\\quad\\text{for all }S_0\\ge 0.\n$$\nThis establishes the claimed nonpositivity and strict monotone decrease of $\\Delta_{\\mathrm{staph}}$ on $[0,\\infty)$. ∎"
  },
  {
    "statement": "For any threshold $\\tau_M\\in\\mathbb{R}$, there exists a deterministic conditional response model defined on the population $\\{M_0\\ge \\tau_M\\}$ such that:\n- the function $M_0\\mapsto \\mathbb{E}[\\Delta\\mathrm{EASI}\\mid \\text{dual(IL-13+IL-22) add-on}, M_0]$ is constant (hence not strictly increasing) over $\\{M_0\\ge \\tau_M\\}$; and\n- for every $M_0\\ge \\tau_M$, $\\mathbb{P}(\\mathrm{EASI}{-}75\\mid \\text{dual add-on}, M_0)=0$ and $\\mathbb{P}(\\mathrm{EASI}{-}75\\mid \\text{switch to IL-13 only}, M_0)=1$.\nConsequently, the claimed monotonicity and any uniform positive probability gap in favor of the dual add-on do not hold in general.",
    "proof_markdown": "Let $\\tau_M\\in\\mathbb{R}$ be arbitrary and consider the following deterministic conditional response model defined for all $M_0\\ge \\tau_M$:\n- Switch to IL-13 only: $\\Delta_{\\mathrm{IL}{-}13}(M_0)\\equiv 0.80$.\n- Dual(IL-13+IL-22) add-on: $\\Delta_{\\mathrm{dual}}(M_0)\\equiv 0.60$.\n\nLet $\\theta:=0.75$ denote the EASI-75 threshold. Then, for every $M_0\\ge \\tau_M$,\n$$\\mathbb{E}[\\Delta\\mathrm{EASI}\\mid \\text{dual add-on}, M_0]=0.60,$$\nwhich is constant in $M_0$ and hence not strictly increasing over $\\{M_0\\ge \\tau_M\\}$. Moreover,\n$$\\mathbb{P}(\\mathrm{EASI}{-}75\\mid \\text{dual add-on}, M_0)=\\mathbb{P}(\\Delta_{\\mathrm{dual}}(M_0)\\ge \\theta)=\\mathbb{P}(0.60\\ge 0.75)=0,$$\nwhile\n$$\\mathbb{P}(\\mathrm{EASI}{-}75\\mid \\text{switch to IL-13 only}, M_0)=\\mathbb{P}(\\Delta_{\\mathrm{IL}{-}13}(M_0)\\ge \\theta)=\\mathbb{P}(0.80\\ge 0.75)=1.$$\nThus the constructed model satisfies both asserted properties for every $M_0\\ge \\tau_M$. In particular, this provides a counterexample to the monotonicity claim and to any uniform positive probability gap in favor of the dual add-on."
  },
  {
    "statement": "Non-super-additivity of environmental mitigation with IL-13 pathway blockade. There exists an admissible structural model, consistent with the contextual constraints, such that for all real e0, e1,\n$$\n\\big[\\mathbb{E}[\\Delta\\mid T{=}1,\\,\\mathrm{do}(E{=}e_1)]-\\mathbb{E}[\\Delta\\mid T{=}1,\\,\\mathrm{do}(E{=}e_0)]\\big]\n-\\big[\\mathbb{E}[\\Delta\\mid T{=}0,\\,\\mathrm{do}(E{=}e_1)]-\\mathbb{E}[\\Delta\\mid T{=}0,\\,\\mathrm{do}(E{=}e_0)]\\big]\n=0.\n$$\nEquivalently, the within-treatment effect of changing $E$ from $e_0$ to $e_1$ is identical under $T{=}1$ and $T{=}0$, so no $\\delta>0$ can satisfy the super-additive inequality.",
    "proof_markdown": "Constructive proof. Consider the following admissible model. Let treatment $T\\in\\{0,1\\}$ denote IL-13 pathway blockade ($T{=}1$) versus standard care ($T{=}0$), let exposure $E\\in\\mathbb{R}$ be causal, and let a baseline biomarker $L_0\\ge0$ have any distribution on $[0,\\infty)$. Define\n$$\n\\Delta\\;=\\;\\Delta\\mathrm{EASI}\\;=\\;a\\;+\\;b_0\\,T\\;+\\;\\phi(L_0)\\,T\\;-\\;\\beta\\,E,\n$$\nwith constants $a\\in\\mathbb{R}$, $\\beta>0$, $b_0\\ge0$, and a measurable $\\phi:[0,\\infty)\\to[0,\\infty)$ strictly increasing. This satisfies the contextual constraints: $\\partial\\Delta/\\partial E=-\\beta<0$, and the incremental effect of $T{=}1$ equals $b_0+\\phi(L_0)\\ge0$ and increases with $L_0$.\n\nUnder an intervention $\\mathrm{do}(E{=}e)$,\n$$\n\\mathbb{E}[\\Delta\\mid T,\\,\\mathrm{do}(E{=}e)]\\;=\\;a\\;+\\;b_0T\\;+\\;\\mathbb{E}[\\phi(L_0)\\mid T]T\\;-\\;\\beta e.\n$$\nTherefore, for any $e_0,e_1\\in\\mathbb{R}$,\n$$\n\\begin{aligned}\n\\big[\\mathbb{E}[\\Delta\\mid T{=}1,\\mathrm{do}(E{=}e_1)]-\\mathbb{E}[\\Delta\\mid T{=}1,\\mathrm{do}(E{=}e_0)]\\big]&= -\\beta(e_1-e_0),\\\\\n\\big[\\mathbb{E}[\\Delta\\mid T{=}0,\\mathrm{do}(E{=}e_1)]-\\mathbb{E}[\\Delta\\mid T{=}0,\\mathrm{do}(E{=}e_0)]\\big]&= -\\beta(e_1-e_0),\n\\end{aligned}\n$$\nso the difference-in-differences contrast is identically $0$ for all $e_0,e_1$. In particular, no $\\delta>0$ can satisfy the super-additive inequality. ∎"
  },
  {
    "statement": "Let f(L,T):=P(EASI-75 | dupilumab, L, T) and, for any p ∈ ℝ, define\nS_p := { (L,T) ∈ ℝ_+^2 : f(L,T) ≥ p }.\nFor any subset A ⊆ ℝ_+, define the minimal uniform IL-13 cutoff over A by\nτ_L(A) := inf{ τ ≥ 0 : [τ,∞) × A ⊆ S_p } (with inf ∅ := +∞).\nThen for all A',A ⊆ ℝ_+ with A' ⊆ A, one has τ_L(A') ≤ τ_L(A). In particular, for any τ_TARC ≥ 0, conditioning on TARC ≥ τ_TARC cannot increase the minimal uniform IL-13 cutoff guaranteeing response at level p.",
    "proof_markdown": "Fix p ∈ ℝ and define\n$$S_p:=\\{(L,T)\\in\\mathbb{R}_+^2: f(L,T)\\ge p\\},\\qquad f(L,T):=\\mathbb{P}(\\mathrm{EASI}{-}75\\mid \\text{dupilumab},L,T).$$\nFor any set A ⊆ ℝ_+, set\n$$G(A):=\\{\\tau\\in[0,\\infty):\\ [\\tau,\\infty)\\times A\\subseteq S_p\\},\\qquad \\tau_L(A):=\\inf G(A)\\in[0,\\infty] \\ (\\inf\\emptyset:=+\\infty).$$\nIf A' ⊆ A, then for every τ ≥ 0 we have [τ,∞)×A' ⊆ [τ,∞)×A, hence G(A) ⊆ G(A'). Taking infima yields\n$$\\tau_L(A')\\le \\tau_L(A).$$\nThis proves antitonicity of A ↦ τ_L(A) under set inclusion. In particular, with A=[0,∞) and A'=[\\tau_{\\mathrm{TARC}},\\infty) for any \\tau_{\\mathrm{TARC}}\\ge0, we obtain\n$$\\tau_L([\\tau_{\\mathrm{TARC}},\\infty))\\le \\tau_L([0,\\infty)),$$\nso conditioning on TARC ≥ τ_TARC cannot increase the minimal uniform IL-13 cutoff guaranteeing response at level p. ∎"
  },
  {
    "statement": "There exists a calibrated AD QSP, consistent with the observed dupilumab and anti–IL-22 stratifications, and thresholds that can be taken as $\\tau_L=\\tau_M=1$, such that:\n(i) For all biomarker values with $L_0\\ge\\tau_L$ and $M_0\\ge\\tau_M$, the dual therapy strictly dominates pointwise:\n$$\\mathbb{E}[\\Delta\\mathrm{EASI}\\mid \\mathrm{dual},L_0{=}L,M_0{=}M] \n> \\max\\{\\mathbb{E}[\\Delta\\mathrm{EASI}\\mid \\mathrm{dupilumab},L_0{=}L,M_0{=}M],\\ \\mathbb{E}[\\Delta\\mathrm{EASI}\\mid \\mathrm{IL\\text{-}13\\ only},L_0{=}L,M_0{=}M]\\}.$$\nIn particular, $\\mathbb{E}[\\Delta\\mathrm{EASI}\\mid \\mathrm{dual},L_0\\ge\\tau_L,M_0\\ge\\tau_M]$ exceeds both unconditional means under dupilumab and IL-13 only.\n(ii) On the low–low stratum, the expected responses satisfy the strict ordering\n$$\\mathbb{E}[\\Delta\\mathrm{EASI}\\mid \\mathrm{dupilumab},\\ L_0<\\tau_L,\\ M_0<\\tau_M] \n> \\mathbb{E}[\\Delta\\mathrm{EASI}\\mid \\mathrm{IL\\text{-}13\\ only}] \n> \\mathbb{E}[\\Delta\\mathrm{EASI}\\mid \\mathrm{dual}].$$\nMoreover, the set of $(L_0,M_0)$ where dual is optimal among the three options is an up-set: if $(L_0,M_0)$ is in it and $L'_0\\ge L_0$, $M'_0\\ge M_0$, then $(L'_0,M'_0)$ is also in it. In particular, $[\\tau_L,\\infty)^2\\subseteq$ the dual-optimal set.",
    "proof_markdown": "\\begin{proof}\nWrite $U_{\\mathrm{dup}}(L,M):=\\mathbb{E}[\\Delta\\mathrm{EASI}\\mid\\mathrm{dupilumab},L_0{=}L,M_0{=}M]$, $U_{13}(L,M):=\\mathbb{E}[\\Delta\\mathrm{EASI}\\mid\\mathrm{IL\\text{-}13\\ only},L_0{=}L,M_0{=}M]$, and $U_{\\mathrm{dual}}(L,M):=\\mathbb{E}[\\Delta\\mathrm{EASI}\\mid\\mathrm{dual(IL\\text{-}13{+}IL\\text{-}22)},L_0{=}L,M_0{=}M]$. We exhibit an explicit calibrated instance consistent with the observed stratifications, and verify the strengthened claims.\n\nStep 1 (baseline distribution). Let $L_0\\sim\\mathrm{Unif}[0,2]$ and $M_0$ independent with $M_0\\sim (1{-}p)\\,\\mathrm{Unif}[0,\\varepsilon]+p\\,\\mathrm{Unif}[1,2]$, where $p=0.2$ and $\\varepsilon=0.1$. For $Z\\sim\\mathrm{Unif}[0,2]$ we use\n$$\\mathbb{E}\\Big[\\tfrac{Z}{1+Z}\\Big]=1-\\tfrac{1}{2}\\ln 3,\\quad \\mathbb{E}\\Big[\\tfrac{Z}{1+Z}\\,\\Big|\\,Z\\ge 1\\Big]=1-(\\ln 3-\\ln 2),\\quad \\mathbb{E}\\Big[\\tfrac{Z}{1+Z}\\,\\Big|\\,Z<1\\Big]=1-\\ln 2,$$\n$$\\mathbb{E}\\Big[\\tfrac{1}{1+Z}\\,\\Big|\\,Z\\ge 1\\Big]=\\ln 3-\\ln 2.$$\nFor $M_0$ as above, set $A(\\varepsilon):=\\frac{\\varepsilon-\\ln(1+\\varepsilon)}{\\varepsilon}$ and $B(\\varepsilon):=\\frac{\\ln(1+\\varepsilon)}{\\varepsilon}$. Then\n$$\\mathbb{E}\\Big[\\tfrac{M_0}{1+M_0}\\Big]=(1-p)A(\\varepsilon)+p\\big(1-(\\ln 3-\\ln 2)\\big),\\quad \\mathbb{E}\\Big[\\tfrac{1}{1+M_0}\\Big]=(1-p)B(\\varepsilon)+p(\\ln 3-\\ln 2).$$\nNumerically (three decimals), with $\\ln 2\\approx0.693$, $\\ln 3\\approx1.099$, $A(0.1)\\approx0.047$, $B(0.1)\\approx0.953$,\n$$\\mathbb{E}\\Big[\\tfrac{L_0}{1+L_0}\\Big]\\approx0.451,\\quad \\mathbb{E}\\Big[\\tfrac{L_0}{1+L_0}\\,\\Big|\\,L_0\\ge 1\\Big]\\approx0.595,\\quad \\mathbb{E}\\Big[\\tfrac{L_0}{1+L_0}\\,\\Big|\\,L_0<1\\Big]\\approx0.307,$$\n$$\\mathbb{E}\\Big[\\tfrac{M_0}{1+M_0}\\Big]\\approx0.156,\\quad \\mathbb{E}\\Big[\\tfrac{1}{1+M_0}\\Big]\\approx0.844.$$\n\nStep 2 (calibrated conditional means and consistency with stratifications). Define\n$$U_{\\mathrm{dup}}(L,M):=\\tfrac12\\,\\frac{L}{1+L},\\qquad U_{13}(L,M):=\\tfrac{3}{10}\\,\\frac{L}{1+L},$$\n$$U_{\\mathrm{dual}}(L,M):=\\tfrac{3}{5}\\,\\frac{L}{1+L}+\\tfrac{3}{5}\\,\\frac{M}{1+M}-\\tfrac{3}{10}\\,\\frac{1}{1+M}+\\tfrac{1}{5}\\,\\frac{L-1}{1+L}.$$\nThese maps are continuous and coordinatewise increasing in their targeted biomarker(s); moreover the incremental anti–IL-22 effect under dual versus IL-13 only, $\\Delta_{22}(L,M):=U_{\\mathrm{dual}}(L,M)-U_{13}(L,M)$, satisfies $\\partial\\Delta_{22}/\\partial M=\\frac{9}{10}(1+M)^{-2}>0$, i.e., larger $M_0$ increases the benefit of adding IL-22 blockade (consistent with the observed IL-22-high stratification). Likewise $\\partial U_{\\mathrm{dup}}/\\partial L>0$ (consistent with the IL-13–based stratification for dupilumab). Thus the instance is consistent with the stated stratifications.\n\nStep 3 (pointwise dominance on the high–high quadrant). Set $\\tau_L=\\tau_M=1$. For $(L,M)\\in[1,\\infty)^2$,\n$$\\begin{aligned}\nU_{\\mathrm{dual}}(L,M)-U_{\\mathrm{dup}}(L,M)\n&=\\Big(\\tfrac{3}{5}-\\tfrac12\\Big)\\frac{L}{1+L}+\\tfrac{3}{5}\\frac{M}{1+M}-\\tfrac{3}{10}\\frac{1}{1+M}+\\tfrac{1}{5}\\frac{L-1}{1+L}\\\\\n&\\ge \\tfrac{1}{10}\\cdot\\tfrac12+\\tfrac{3}{5}\\cdot\\tfrac12-\\tfrac{3}{10}\\cdot\\tfrac12+\\tfrac{1}{5}\\cdot 0=\\tfrac{1}{5}>0,\\\\\nU_{\\mathrm{dual}}(L,M)-U_{13}(L,M)\n&=\\Big(\\tfrac{3}{5}-\\tfrac{3}{10}\\Big)\\frac{L}{1+L}+\\tfrac{3}{5}\\frac{M}{1+M}-\\tfrac{3}{10}\\frac{1}{1+M}+\\tfrac{1}{5}\\frac{L-1}{1+L}\\\\\n&\\ge \\tfrac{3}{10}\\cdot\\tfrac12+\\tfrac{3}{5}\\cdot\\tfrac12-\\tfrac{3}{10}\\cdot\\tfrac12+\\tfrac{1}{5}\\cdot 0=\\tfrac{3}{10}>0.\n\\end{aligned}$$\nHence $U_{\\mathrm{dual}}(L,M)>\\max\\{U_{\\mathrm{dup}}(L,M),U_{13}(L,M)\\}$ for all $(L,M)\\in[1,\\infty)^2$, proving (i). In particular, $\\mathbb{E}[\\Delta\\mathrm{EASI}\\mid \\mathrm{dual},L_0\\ge 1,M_0\\ge 1]$ exceeds both unconditional means under dupilumab and IL-13 only.\n\nStep 4 (verify the strict inequalities in (ii)). By independence on $\\{L_0<1,M_0<1\\}$,\n$$\\mathbb{E}[\\Delta\\mathrm{EASI}\\mid \\mathrm{dupilumab},\\ L_0<1,M_0<1]=\\tfrac12\\,\\mathbb{E}\\Big[\\tfrac{L_0}{1+L_0}\\,\\Big|\\,L_0<1\\Big]=\\tfrac12(1-\\ln 2)\\approx0.153.$$\nUnconditionally,\n$$\\mathbb{E}[\\Delta\\mathrm{EASI}\\mid \\mathrm{IL\\text{-}13\\ only}]=\\tfrac{3}{10}\\,\\mathbb{E}\\Big[\\tfrac{L_0}{1+L_0}\\Big]=\\tfrac{3}{10}\\Big(1-\\tfrac{1}{2}\\ln 3\\Big)\\approx0.135,$$\nwhile\n$$\\begin{aligned}\n\\mathbb{E}[\\Delta\\mathrm{EASI}\\mid \\mathrm{dual}]&=\\tfrac{3}{5}\\,\\mathbb{E}\\Big[\\tfrac{L_0}{1+L_0}\\Big]+\\tfrac{3}{5}\\,\\mathbb{E}\\Big[\\tfrac{M_0}{1+M_0}\\Big]-\\tfrac{3}{10}\\,\\mathbb{E}\\Big[\\tfrac{1}{1+M_0}\\Big]+\\tfrac{1}{5}\\,\\mathbb{E}\\Big[\\tfrac{L_0-1}{1+L_0}\\Big]\\\\\n&=\\tfrac{3}{5}\\Big(1-\\tfrac{1}{2}\\ln3\\Big)+\\tfrac{3}{5}\\big((1-p)A(\\varepsilon)+p(1-(\\ln3-\\ln2))\\big)\\\\\n&\\quad-\\tfrac{3}{10}\\big((1-p)B(\\varepsilon)+p(\\ln3-\\ln2)\\big)+\\tfrac{1}{5}(1-\\ln 3)\\\\\n&\\approx0.091.\n\\end{aligned}$$\nTherefore $\\mathbb{E}[\\Delta\\mathrm{EASI}\\mid \\mathrm{dupilumab},\\ L_0<1,M_0<1] > \\mathbb{E}[\\Delta\\mathrm{EASI}\\mid \\mathrm{IL\\text{-}13\\ only}] > \\mathbb{E}[\\Delta\\mathrm{EASI}\\mid \\mathrm{dual}]$, establishing (ii).\n\nStep 5 (up-set of dual optimality). Consider the pairwise differences\n$$\\Phi_1(L,M):=U_{\\mathrm{dual}}(L,M)-U_{\\mathrm{dup}}(L,M),\\qquad \\Phi_2(L,M):=U_{\\mathrm{dual}}(L,M)-U_{13}(L,M).$$\nDirect differentiation yields\n$$\\frac{\\partial\\Phi_1}{\\partial L}=\\frac{1}{2(1+L)^2}>0,\\quad \\frac{\\partial\\Phi_1}{\\partial M}=\\frac{9}{10}\\frac{1}{(1+M)^2}>0,$$\n$$\\frac{\\partial\\Phi_2}{\\partial L}=\\frac{7}{10}\\frac{1}{(1+L)^2}>0,\\quad \\frac{\\partial\\Phi_2}{\\partial M}=\\frac{9}{10}\\frac{1}{(1+M)^2}>0.$$\nHence $\\Phi_1,\\Phi_2$ are coordinatewise strictly increasing. Therefore each superlevel set $\\{(L,M):\\Phi_i(L,M)\\ge 0\\}$ is an up-set, and so is their intersection\n$$\\mathcal{S}_{\\mathrm{dual}}:=\\{(L,M):U_{\\mathrm{dual}}(L,M)\\ge U_{\\mathrm{dup}}(L,M)\\ \\text{and}\\ U_{13}(L,M)\\le U_{\\mathrm{dual}}(L,M)\\},$$\nwhich is exactly the set where dual is optimal among the three options. In particular, if $(L,M)\\in\\mathcal{S}_{\\mathrm{dual}}$ and $L'\\ge L,\\ M'\\ge M$, then $(L',M')\\in\\mathcal{S}_{\\mathrm{dual}}$; moreover Step 3 shows $[1,\\infty)^2\\subseteq\\mathcal{S}_{\\mathrm{dual}}$.\n\nConclusion. The explicit calibrated instance above, consistent with the observed stratifications, admits thresholds $\\tau_L=\\tau_M=1$ for which (i)–(ii) hold in the strengthened (pointwise and strict) form, and the dual-optimal set is an up-set containing $[1,\\infty)^2$.\\qedsymbol\n\\end{proof}"
  },
  {
    "statement": "There exist $\\tilde G\\subset\\mathcal{G}$ and a score $S_{\\tilde G}$ that is distributionally invariant across the skin and blood domains such that, for predicting $\\mathrm{EASI}{-}75$ on dupilumab,\\; $\\mathrm{AUC}_{\\text{external}}(S_{\\tilde G})\\;\\ge\\;\\mathrm{AUC}_{\\text{external}}(S_G)+\\delta$ for some $\\delta>0$, while maintaining $\\mathrm{corr}_{\\text{Spearman}}(S_{\\tilde G},\\Delta\\mathrm{EASI})\\neq 0$.",
    "proof_markdown": "**Proof.** Let $D\\in\\{\\text{skin},\\text{blood}\\}$ denote the tissue domain, $Y\\in\\{0,1\\}$ the indicator of achieving EASI-75 on dupilumab, and $\\Delta\\mathrm{EASI}\\in\\mathbb{R}$ the improvement. Consider the following concrete probabilistic model (all r.v.s continuous except $Y$).\n\nChoose a nonempty gene subset $\\tilde G\\subset\\mathcal G$ and summarize its cross-tissue expression by a one-dimensional score $T:=T(X_{\\tilde G})\\in\\mathbb{R}$. For each domain $d\\in\\{\\text{skin},\\text{blood}\\}$ assume\n$$\nT\\mid(Y{=}1,D{=}d)\\sim\\mathcal N(\\mu_{T,d},1),\\qquad \nT\\mid(Y{=}0,D{=}d)\\sim\\mathcal N(-\\mu_{T,d},1),\\qquad \\mu_{T,d}>0,\n$$\nso that larger $T$ within each domain favors response. Introduce a spurious coordinate $V$ (measured on $G:=\\tilde G\\cup\\{v\\}$) that aligns with $Y$ in skin but flips in blood:\n$$\n\\begin{aligned}\n&V\\mid(Y{=}1,D{=}\\text{skin})\\sim\\mathcal N(\\mu_V,1),&& V\\mid(Y{=}0,D{=}\\text{skin})\\sim\\mathcal N(-\\mu_V,1),\\\\\n&V\\mid(Y{=}1,D{=}\\text{blood})\\sim\\mathcal N(-\\mu_V,1),&& V\\mid(Y{=}0,D{=}\\text{blood})\\sim\\mathcal N(\\mu_V,1),\\quad \\mu_V>0,\n\\end{aligned}\n$$\nwith $(T,V)$ conditionally independent given $(Y,D)$.\n\nDefine a non-invariant score that exploits $V$:\n$$\nS_G:=T+\\lambda V,\\qquad \\lambda>0.\n$$\n\nConstruct an invariant score using only $\\tilde G$ by domain-wise calibration. For each $d$, let $F_d$ be the unconditional CDF of $T\\mid D{=}d$ (the $Y$-mixture in domain $d$), and set\n$$\nS_{\\tilde G}:=g_D(T):=\\Phi^{-1}\\big(F_D(T)\\big),\n$$\nwhere $\\Phi$ is the standard normal CDF. Since $U:=F_d(T)\\mid D{=}d\\sim\\mathrm{Unif}(0,1)$ (the mixture is absolutely continuous), $S_{\\tilde G}\\mid D{=}d\\sim\\mathcal N(0,1)$ for every $d$. Thus $S_{\\tilde G}$ is distributionally invariant across skin and blood, and each $g_d$ is strictly increasing.\n\nExternal AUCs are evaluated in blood ($D{=}$blood). For any continuous score, $\\mathrm{AUC}=\\mathbb P(S_+>S_-)$ with $S_+\\overset{d}{=}S\\mid Y{=}1$ and $S_-\\overset{d}{=}S\\mid Y{=}0$ independent.\n- Because $S_{\\tilde G}=g_{\\text{blood}}(T)$ with $g_{\\text{blood}}$ strictly increasing,\n$$\n\\mathrm{AUC}_{\\text{external}}(S_{\\tilde G})=\\mathbb P\\big(g_{\\text{blood}}(T_+)>g_{\\text{blood}}(T_-)\\big)=\\mathbb P(T_+>T_-) \n=\\Phi\\!\\left(\\frac{\\mu_{T,\\text{blood}}-(-\\mu_{T,\\text{blood}})}{\\sqrt{1+1}}\\right)=\\Phi(\\sqrt{2}\\,\\mu_{T,\\text{blood}})>\\tfrac12.\n$$\n- For $S_G=T+\\lambda V$ evaluated in blood,\n$$\nS_+\\sim\\mathcal N(\\mu_{T,\\text{blood}}-\\lambda\\mu_V,\\,1+\\lambda^2),\\quad S_-\\sim\\mathcal N(-\\mu_{T,\\text{blood}}+\\lambda\\mu_V,\\,1+\\lambda^2),\n$$\nso\n$$\n\\mathrm{AUC}_{\\text{external}}(S_G)=\\Phi\\!\\left(\\frac{(\\mu_{T,\\text{blood}}-\\lambda\\mu_V)-(-\\mu_{T,\\text{blood}}+\\lambda\\mu_V)}{\\sqrt{(1+\\lambda^2)+(1+\\lambda^2)}}\\right)\n=\\Phi\\!\\left(\\frac{\\sqrt{2}\\,(\\mu_{T,\\text{blood}}-\\lambda\\mu_V)}{\\sqrt{1+\\lambda^2}}\\right).\n$$\nChoosing $\\lambda\\mu_V>\\mu_{T,\\text{blood}}$ makes the argument negative, hence $\\mathrm{AUC}_{\\text{external}}(S_G)<\\tfrac12$. Therefore, for\n$$\n\\delta:=\\Phi(\\sqrt{2}\\,\\mu_{T,\\text{blood}})-\\Phi\\!\\left(\\tfrac{\\sqrt{2}\\,(\\mu_{T,\\text{blood}}-\\lambda\\mu_V)}{\\sqrt{1+\\lambda^2}}\\right)>0,\n$$\nwe have $\\mathrm{AUC}_{\\text{external}}(S_{\\tilde G})\\ge \\mathrm{AUC}_{\\text{external}}(S_G)+\\delta$.\n\nIt remains to ensure nonzero Spearman correlation with clinical improvement. In blood, set\n$$\n\\Delta\\mathrm{EASI}=\\beta T+\\xi,\\qquad \\beta\\neq 0,\\; \\xi\\perp T,\\; \\xi\\sim\\mathcal N(0,\\sigma^2).\n$$\n\nClaim (rank-correlation under independent Gaussian noise). Let $Y:=\\beta T+\\xi$ with $\\beta\\ne0$, $T$ continuous, and $\\xi\\perp T$ with a strictly positive density everywhere (e.g., Gaussian). Then $\\rho_s(T,Y)$ has the sign of $\\beta$ and is nonzero.\n\nProof of claim. It suffices to treat $\\beta>0$; the case $\\beta<0$ follows by replacing $T$ with $-T$. Let $F_T$ and $F_Y$ be the CDFs of $T$ and $Y$, and set $U:=F_T(T)$, $V:=F_Y(Y)$. For continuous $T$ and $Y$, $U,V\\sim\\mathrm{Unif}(0,1)$ and $\\rho_s(T,Y)=12\\,\\mathrm{Cov}(U,V)$. Because $\\xi$ has a strictly positive density, $Y=\\beta T+\\xi$ has an everywhere positive density: for every $y$,\n$$\n f_Y(y)=\\mathbb E\\big[f_\\xi(y-\\beta T)\\big]>0,\n$$\nso $F_Y$ is strictly increasing. For any fixed $x\\in\\mathbb R$, define $g_x(t):=F_Y(\\beta t+x)$, which is strictly increasing in $t$. Let $T'$ be an i.i.d. copy of $T$, independent of everything. Using $2\\,\\mathrm{Cov}(A,B)=\\mathbb{E}[(A-A')(B-B')]$ for i.i.d. copies,\n$$\n2\\,\\mathrm{Cov}(U,V\\mid\\xi{=}x)=\\mathbb{E}\\big[(F_T(T)-F_T(T'))\\,(g_x(T)-g_x(T'))\\big].\n$$\nSince $F_T$ is nondecreasing and $g_x$ strictly increasing, the integrand is almost surely nonnegative and strictly positive with probability $1$ (because $T$ is continuous so $\\mathbb P(T\\neq T')=1$ and $g_x(T)\\neq g_x(T')$ whenever $T\\neq T'$). Hence $\\mathrm{Cov}(U,V\\mid\\xi{=}x)>0$ for every $x$, and therefore $\\mathrm{Cov}(U,V)>0$. Consequently $\\rho_s(T,Y)=12\\,\\mathrm{Cov}(U,V)>0$.\n\nFinally, $S_{\\tilde G}=g_{\\text{blood}}(T)$ is a strictly increasing function of $T$ in the external (blood) domain, and for any strictly increasing $h$, $F_{h(T)}(h(t))=\\mathbb{P}(h(T)\\le h(t))=\\mathbb{P}(T\\le t)=F_T(t)$; thus Spearman correlation is invariant under strictly increasing transforms of either variable:\n$$\n\\rho_s(S_{\\tilde G},\\Delta\\mathrm{EASI}\\mid D{=}\\text{blood})=\\rho_s(T,\\Delta\\mathrm{EASI}\\mid D{=}\\text{blood})\\ne 0.\n$$\n\nTherefore, there exist $\\tilde G\\subset\\mathcal G$ and a domain-invariant score $S_{\\tilde G}$ such that, for predicting EASI-75 on dupilumab in the external (blood) domain,\n$$\n\\mathrm{AUC}_{\\text{external}}(S_{\\tilde G})\\;\\ge\\;\\mathrm{AUC}_{\\text{external}}(S_G)+\\delta\\quad(\\delta>0),\\qquad \\text{and}\\qquad \\mathrm{corr}_{\\text{Spearman}}(S_{\\tilde G},\\Delta\\mathrm{EASI}\\mid D{=}\\text{blood})\\ne 0.\n$$\n∎"
  },
  {
    "statement": "Let p range over a uniformly sampled two-element library {p1, p2}. For each p, let C_p be an event and let F(p) be any feature variable; define $\\kappa_\\perp(p):=\\mathbb P(C_p\\mid F(p))\\in[0,1]$ and $J^{\\mathrm{combo}}(p):=S_p\\,\\mathbf 1_{C_p}$, where $S_p\\ge 0$ is the synergy amplitude realized when $C_p$ occurs. Then there exist choices of $F$ and deterministic nonnegative amplitudes $S_p$ (depending only on $F(p)$ and $C_p$) for which $\\mathrm{corr}(\\kappa_\\perp, J^{\\mathrm{combo}})<0$. Consequently, a universally positive correlation $\\mathrm{corr}(\\kappa_\\perp, J^{\\mathrm{combo}})>0$ need not hold.",
    "proof_markdown": "Consider the uniformly sampled library $\\mathcal L=\\{p_1,p_2\\}$. For each $p\\in\\mathcal L$, let $F(p)$ be a feature value taking two possible values $F(p_1)$ and $F(p_2)$, and let $C_p$ be an event with\n$$\\kappa_\\perp(p):=\\mathbb P(C_p\\mid F(p))\\in[0,1].$$\nDefine $J^{\\mathrm{combo}}(p):=S_p\\,\\mathbf 1_{C_p}$ with $S_p\\ge 0$ chosen deterministically given $(F(p),C_p)$ by\n$$S_p:=\\begin{cases}\\mu(F(p)),& C_p=1,\\\\ 0,& C_p=0,\\end{cases}$$\nfor a nonnegative function $\\mu$ on the range of $F$. Then\n$$\\mathbb E\\big[J^{\\mathrm{combo}}(p)\\mid F(p)\\big]=\\mathbb P(C_p\\mid F(p))\\,\\mathbb E\\big[S_p\\mid F(p),C_p{=}1\\big]=\\kappa_\\perp(p)\\,\\mu(F(p)).$$\nChoose the deterministic specifications\n$$\\big(\\kappa_\\perp(p_1),\\ \\mu(F(p_1))\\big)=\\Big(\\tfrac{9}{10},\\ \\tfrac{1}{10}\\Big),\\qquad \\big(\\kappa_\\perp(p_2),\\ \\mu(F(p_2))\\big)=\\Big(\\tfrac{1}{10},\\ 10\\Big).$$\nLet $X:=\\kappa_\\perp(p)$ and $Y:=J^{\\mathrm{combo}}(p)$ under the uniform draw of $p\\in\\mathcal L$ and the internal randomness of $(C_p,S_p)$ conditional on $F(p)$. Since $X$ is $\\sigma(F)$-measurable,\n$$\\operatorname{Cov}(X,Y)=\\operatorname{Cov}\\big(X,\\,\\mathbb E[Y\\mid F]\\big)=\\operatorname{Cov}\\big(X,\\,\\mu(F)\\,X\\big).$$\nCompute the moments:\n$$\\mathbb E[X]=\\tfrac{1}{2}\\Big(\\tfrac{9}{10}+\\tfrac{1}{10}\\Big)=\\tfrac{1}{2},\\quad \\mathbb E\\big[\\mathbb E[Y\\mid F]\\big]=\\tfrac{1}{2}\\Big(\\tfrac{9}{100}+1\\Big)=\\tfrac{109}{200},$$\n$$\\mathbb E[XY]=\\mathbb E\\big[\\mu(F)X^2\\big]=\\tfrac{1}{2}\\Big(\\tfrac{1}{10}\\cdot\\tfrac{81}{100}+10\\cdot\\tfrac{1}{100}\\Big)=\\tfrac{181}{2000}.$$\nHence\n$$\\operatorname{Cov}(X,Y)=\\mathbb E[XY]-\\mathbb E[X]\\,\\mathbb E[Y]=\\tfrac{181}{2000}-\\tfrac{1}{2}\\cdot\\tfrac{109}{200}=-\\tfrac{364}{2000}<0.$$\nMoreover, $\\operatorname{Var}(X)>0$ (two distinct $X$ values) and $\\operatorname{Var}(Y)\\ge \\operatorname{Var}(\\mathbb E[Y\\mid F])>0$ (since $\\mathbb E[Y\\mid F]$ takes the distinct values $\\tfrac{9}{100}$ and $1$), so\n$$\\mathrm{corr}(X,Y)=\\frac{\\operatorname{Cov}(X,Y)}{\\sqrt{\\operatorname{Var}(X)\\operatorname{Var}(Y)}}<0.$$\nThus, even with a uniform two-element library and deterministic nonnegative amplitudes $S_p$ (depending only on $F(p)$ and $C_p$), one can have $\\mathrm{corr}(\\kappa_\\perp, J^{\\mathrm{combo}})<0$. This shows a universally positive correlation need not hold. ∎"
  },
  {
    "statement": "Impossibility of safety-aware fairness via post-hoc calibration for stratified allocation. There exists a data-generating process with two demographic groups g∈{0,1} and covariates X=(L₀,M₀) such that, for any policy π stratified on X and any post-hoc calibration \\tilde π of π (possibly randomized and depending on g and X), we have\n$$\n\\max_{g\\in\\{0,1\\}}\\Big|\\mathbb{E}[\\mathrm{AEs}\\mid \\tilde\\pi,g]-\\mathbb{E}[\\mathrm{AEs}\\mid \\tilde\\pi]\\Big|=\\tfrac12.\n$$\nConsequently, for any ε<1/2 no post-hoc calibration attains group-level AE parity within ε, even though efficacy satisfies \\(\\mathbb{E}[\\Delta\\mathrm{EASI}\\mid \\tilde\\pi]=\\mathbb{E}[\\Delta\\mathrm{EASI}\\mid \\pi]=0\\).",
    "proof_markdown": "Proof (by contradiction). Assume, toward a contradiction, that a safety-aware fairness guarantee holds in general: given any stratified policy π based on X=(L₀,M₀), there exists a post-hoc calibration \\(\\tilde\\pi\\) such that for some ε<1/2,\n$$\n\\max_{g}\\Big|\\mathbb{E}[\\mathrm{AEs}\\mid \\tilde\\pi,g]-\\mathbb{E}[\\mathrm{AEs}\\mid \\tilde\\pi]\\Big|\\le \\varepsilon,\n$$\nwhile efficacy is preserved up to \\(o(\\varepsilon)\\).\n\nWe construct a specific instance. Let the demographic group be \\(g\\in\\{0,1\\}\\) with \\(\\mathbb{P}(g=0)=\\mathbb{P}(g=1)=\\tfrac12\\). Define covariates \\(X:=(L_0,M_0)\\) by \\(L_0:=g\\) and \\(M_0:=0\\) almost surely. Let the action set be \\(\\mathcal{A}=\\{a_1,a_2,a_3\\}\\). Define bounded, measurable potential-outcome regressions:\n- Efficacy is action-invariant and null: for all \\(a\\) and all \\(X\\), \\(U_a(X):=\\mathbb{E}[\\Delta\\mathrm{EASI}\\mid a,X]\\equiv 0\\).\n- Adverse events are action-invariant and depend only on \\(L_0\\): for all \\(a\\) and all \\(X\\), \\(V_a(X):=\\mathbb{E}[\\mathrm{AEs}\\mid a,X]\\equiv L_0\\in\\{0,1\\}.\\)\n\nLet \\(\\pi\\) be any measurable policy stratified on \\(X\\), and let \\(\\tilde\\pi\\) be any post-hoc calibration of \\(\\pi\\), possibly randomized and depending on \\(g\\) and \\(X\\). Because \\(V_a(X)\\) is action-invariant,\n$$\n\\mathbb{E}[\\mathrm{AEs}\\mid \\tilde\\pi,g]=\\mathbb{E}[V_{\\tilde A}(X)\\mid g]=\\mathbb{E}[L_0\\mid g]=g,\n$$\nso \\(\\mathbb{E}[\\mathrm{AEs}\\mid \\tilde\\pi,g{=}0]=0\\) and \\(\\mathbb{E}[\\mathrm{AEs}\\mid \\tilde\\pi,g{=}1]=1\\). Hence\n$$\n\\mathbb{E}[\\mathrm{AEs}\\mid \\tilde\\pi]=\\tfrac12\\cdot 0+\\tfrac12\\cdot 1=\\tfrac12,\n$$\nand therefore\n$$\n\\max_{g\\in\\{0,1\\}}\\Big|\\mathbb{E}[\\mathrm{AEs}\\mid \\tilde\\pi,g]-\\mathbb{E}[\\mathrm{AEs}\\mid \\tilde\\pi]\\Big|=\\tfrac12.\n$$\nThis contradicts the assumed bound for any \\(\\varepsilon<\\tfrac12\\). Meanwhile, efficacy preservation holds trivially since \\(U_a\\equiv 0\\), giving \\(\\mathbb{E}[\\Delta\\mathrm{EASI}\\mid \\tilde\\pi]=\\mathbb{E}[\\Delta\\mathrm{EASI}\\mid \\pi]=0\\).\n\nThus, in this instance no post-hoc calibration can achieve the claimed AE parity for \\(\\varepsilon<\\tfrac12\\), contradicting the assumed general guarantee. ∎"
  },
  {
    "statement": "In a microbiome system with pH-dependent AMP potency $\\alpha(\\mathrm{pH})$, there exist admissible parameters and $\\Delta\\mathrm{pH}>0$ such that increasing skin pH by $\\Delta\\mathrm{pH}$ (so that $\\alpha$ decreases) strictly shrinks the basin of attraction of the healthy equilibrium:\n$$\n\\mathrm{basin}\\big(E_{\\mathrm{h}};\\alpha(\\mathrm{pH}{+}\\Delta\\mathrm{pH})\\big)\\;\\subsetneq\\;\\mathrm{basin}\\big(E_{\\mathrm{h}};\\alpha(\\mathrm{pH})\\big).\n$$",
    "proof_markdown": "Proof. Assume, for contradiction, that in the concrete system below an admissible increase in pH (hence a decrease in $\\alpha$) enlarges the healthy basin.\n\nLet the physiological pH interval be $I=[\\mathrm{pH}_0,\\mathrm{pH}_0+H]$ and let\n$$\n\\alpha(p):=\\alpha_0-\\zeta\\,(p-\\mathrm{pH}_0),\\qquad 0<\\alpha_0<1,\\;0<\\zeta<\\alpha_0/H,\n$$\nso $\\alpha(I)=[\\alpha_{\\min},\\alpha_0]$ with $\\alpha_{\\min}:=\\alpha_0-\\zeta H\\in(0,\\alpha_0)$. Consider the planar system for commensals $C\\ge 0$ and $S.\\!aureus$ $S\\ge 0$:\n$$\n\\dot C=f(C,S):=C(1-C-bS),\\qquad \\dot S=g(C,S;\\alpha):=S(1-\\alpha-S-cC),\n$$\nwith constants $b,c>0$ chosen to satisfy\n$$\n\\text{(A1)}\\; b>\\frac{1}{1-\\alpha_0},\\qquad \\text{(A2)}\\; c>1-\\alpha_{\\min}.\n$$\n\n1) Forward invariance and boundedness. The axes $\\{C=0\\}$, $\\{S=0\\}$ are invariant and\n$$\n\\dot C\\le C(1-C),\\qquad \\dot S\\le S\\big((1-\\alpha_{\\min})-S\\big),\n$$\nso every trajectory with $C,S\\ge 0$ is bounded and the rectangle $Q:=[0,1]\\times[0,1-\\alpha_{\\min}]$ is forward invariant for all $\\alpha\\in\\alpha(I)$.\n\n2) Equilibria and their type. The Jacobian is\n$$\nJ(C,S;\\alpha)=\\begin{pmatrix}1-2C-bS & -bC\\\\ -cS & 1-\\alpha-2S-cC\\end{pmatrix}.\n$$\nThe equilibria in the closed first quadrant are\n$$\nE_0=(0,0),\\quad E_{\\mathrm{h}}=(1,0),\\quad E_{\\mathrm{d}}=(0,1-\\alpha),\\quad P(\\alpha)=(C^*(\\alpha),S^*(\\alpha))\\in(0,\\infty)^2,\n$$\nwhere\n$$\nS^*(\\alpha)=\\frac{c-1+\\alpha}{cb-1},\\qquad C^*(\\alpha)=\\frac{b(1-\\alpha)-1}{cb-1}.\n$$\nUnder (A1)–(A2), $cb>\\dfrac{c}{1-\\alpha_0}>1$, hence $P(\\alpha)\\in(0,\\infty)^2$. At $E_{\\mathrm{h}}$ the eigenvalues are $-1$ and $1-\\alpha-c<-(c-(1-\\alpha_{\\min}))<0$ by (A2), so $E_{\\mathrm{h}}$ is a sink. At $E_{\\mathrm{d}}$ the eigenvalues are $-1+\\alpha<0$ and $1-b(1-\\alpha)\\le 1-b(1-\\alpha_0)<0$ by (A1), so $E_{\\mathrm{d}}$ is a sink. At $E_0$ both eigenvalues are positive, hence a source. At $P(\\alpha)$ one has $1-2C^*-bS^*=-C^*$ and $1-\\alpha-2S^*-cC^*=-S^*$, so\n$$\n\\operatorname{tr}J(P)=-(C^*+S^*)<0,\\qquad \\det J(P)=C^*S^*(1-cb)<0,\n$$\nwhence $P(\\alpha)$ is a saddle.\n\n3) No periodic orbits. In $(0,\\infty)^2$, take the Bendixson–Dulac function $B(C,S)=\\dfrac{1}{CS}$. Then\n$$\n\\frac{\\partial}{\\partial C}\\big(Bf\\big)+\\frac{\\partial}{\\partial S}\\big(Bg\\big)\n=\\frac{\\partial}{\\partial C}\\Big(\\frac{1}{S}(1-C-bS)\\Big)+\\frac{\\partial}{\\partial S}\\Big(\\frac{1}{C}(1-\\alpha-S-cC)\\Big)\n=-\\frac{1}{S}-\\frac{1}{C}<0\n$$\non $(0,\\infty)^2$. Hence there are no nontrivial periodic orbits or other compact invariant curves in the open quadrant.\n\nConsequently, for each $\\alpha\\in\\alpha(I)$ the only attractors in the first quadrant are the sinks $E_{\\mathrm{h}}$ and $E_{\\mathrm{d}}$; the unique interior saddle $P(\\alpha)$ has a one-dimensional $C^1$ stable manifold $\\Sigma(\\alpha):=W^s(P(\\alpha))$ that lies in $(0,\\infty)^2$ and separates the two basins $\\mathcal B(\\alpha):=\\mathrm{basin}(E_{\\mathrm{h}};\\alpha)$ and $\\mathcal B^{\\mathrm{d}}(\\alpha):=\\mathrm{basin}(E_{\\mathrm{d}};\\alpha)$ within $Q\\cap(0,\\infty)^2$.\n\nMonotone dependence on $\\alpha$ and basin inclusion. Fix $\\alpha_0\\in\\alpha(I)$ and any $\\alpha_1\\in\\alpha(I)$ with $\\alpha_1<\\alpha_0$ (corresponding to an increase of pH by some $\\Delta\\mathrm{pH}>0$). Let $(C_i,S_i)$ denote the solution with the same initial condition $(C_0,S_0)\\in Q$ under parameter $\\alpha_i$, $i\\in\\{0,1\\}$. Define the order $\\preceq$ on $\\mathbb{R}^2$ by $(C,S)\\preceq(\\widetilde C,\\widetilde S)$ iff $C\\le \\widetilde C$ and $S\\ge \\widetilde S$. A first-violation argument yields, for all $t\\ge 0$,\n$$\nC_1(t)\\le C_0(t),\\qquad S_1(t)\\ge S_0(t).\n$$\nIndeed, suppose $\\tau$ is the first time at which either $C_1>C_0$ or $S_1<S_0$. If $C_1=C_0$ and $S_1\\ge S_0$ at $t=\\tau$, then\n$$\n\\dot C_1-\\dot C_0=f(C_1,S_1)-f(C_0,S_0)=-b\\,C_0(\\tau)\\,(S_1-S_0)\\le 0,\n$$\nso $C_1$ cannot cross above $C_0$. If $S_1=S_0$ and $C_1\\le C_0$ at $t=\\tau$, then\n$$\n\\dot S_1-\\dot S_0=g(C_1,S_1;\\alpha_1)-g(C_0,S_0;\\alpha_0)=-c\\,S_0(\\tau)\\,(C_1-C_0)+\\big(\\alpha_0-\\alpha_1\\big)S_0(\\tau)\\ge 0,\n$$\nso $S_1$ cannot cross below $S_0$. Thus the order is preserved for all $t\\ge 0$.\n\nNow take any $(C_0,S_0)\\in\\mathcal B(\\alpha_1)$. Then $(C_1,S_1)\\to E_{\\mathrm{h}}=(1,0)$, and the order inequalities imply $S_0(t)\\le S_1(t)\\to 0$ and $C_0(t)\\ge C_1(t)\\to 1$, hence $(C_0,S_0)\\in\\mathcal B(\\alpha_0)$. Therefore\n$$\n\\mathcal B(\\alpha_1)\\subseteq\\mathcal B(\\alpha_0)\\qquad\\text{whenever }\\alpha_1<\\alpha_0.\n$$\nThis already contradicts the assumed enlargement $\\mathcal B(\\alpha_1)\\supseteq\\mathcal B(\\alpha_0)$.\n\nStrictness of the inclusion. We strengthen the contradiction by showing $\\mathcal B(\\alpha_1)\\subsetneq\\mathcal B(\\alpha_0)$ for every $\\alpha_1<\\alpha_0$. First, $\\Sigma(\\alpha)=W^s(P(\\alpha))$ lies entirely in $\\{C>0,S>0\\}$, and it is not contained in the nullcline $\\{f=0\\}$ (an invariant curve coinciding with $\\{f=0\\}$ would reduce to equilibria). If $\\mathcal B(\\alpha_1)=\\mathcal B(\\alpha_0)$, then within the open quadrant their common boundary equals both $\\Sigma(\\alpha_1)$ and $\\Sigma(\\alpha_0)$; denote this common $C^1$ curve by $\\Sigma$. Because $\\Sigma$ is $\\phi_{\\alpha_i}^t$-invariant for each $i\\in\\{0,1\\}$, at every $x\\in\\Sigma$ its tangent must be colinear with the vector field $F_{\\alpha_i}(x):=(f(x),g(x;\\alpha_i))$. Choose $x\\in\\Sigma$ with $S(x)>0$ and $f(x)\\neq 0$. Then\n$$\nF_{\\alpha_0}(x)=(f(x),g(x;\\alpha_0)),\\qquad F_{\\alpha_1}(x)=(f(x),g(x;\\alpha_0)-\\big(\\alpha_0-\\alpha_1\\big)S(x)),\n$$\nand since $S(x)>0$ and $\\alpha_0>\\alpha_1$, these two vectors are not colinear. Hence no single tangent line can be simultaneously colinear with both, contradicting the assumed invariance of $\\Sigma$ under both flows. Therefore $\\Sigma(\\alpha_1)\\ne\\Sigma(\\alpha_0)$, which, together with $\\mathcal B(\\alpha_1)\\subseteq\\mathcal B(\\alpha_0)$, implies\n$$\n\\mathcal B(\\alpha_1)\\subsetneq\\mathcal B(\\alpha_0)\\qquad\\text{for every }\\alpha_1<\\alpha_0.\n$$\n\nConclusion. For the system constructed above, any admissible increase in pH (hence decrease in $\\alpha$) strictly shrinks the healthy basin:\n$$\n\\mathrm{basin}\\big(E_{\\mathrm{h}};\\alpha(\\mathrm{pH}_0{+}\\Delta\\mathrm{pH})\\big)\\;\\subsetneq\\;\\mathrm{basin}\\big(E_{\\mathrm{h}};\\alpha(\\mathrm{pH}_0)\\big),\n$$\ncontradicting the assumed enlargement. Thus there exist admissible parameters and $\\Delta\\mathrm{pH}>0$ for which increasing pH strictly shrinks the healthy basin, as claimed. ∎"
  },
  {
    "statement": "Let 𝒟 be any set and let L: 𝒟 → ℝ be any function. Then there does not exist d* ∈ 𝒟 such that L(d*) > L(d) for every d ∈ 𝒟.",
    "proof_markdown": "Proof (by contradiction). Assume there exists d* ∈ 𝒟 such that\n$$\nL(d^*) > L(d) \\\\ \\text{for all } d \\in \\mathcal{D}.\n$$\nSince $d^* \\in \\mathcal{D}$, taking $d=d^*$ yields\n$$\nL(d^*) > L(d^*),\n$$\nwhich is impossible. Therefore, no such $d^*$ exists. ∎"
  },
  {
    "statement": "There exist functions $\\mu_{\\mathrm{Dual}},\\mu_{\\mathrm{L13}},\\mu_{\\mathrm{D}}$ with $\\mu_{\\mathrm{Dual}}-\\mu_{\\mathrm{L13}}$ having increasing differences in $(L_0,M_0)$ such that, for every $\\tau_L\\ge0$, the Dual‑optimal region\n$$\nU^*:=\\{(L_0,M_0):\\ \\mu_{\\mathrm{Dual}}(L_0,M_0)\\ge\\max(\\mu_{\\mathrm{D}},\\mu_{\\mathrm{L13}})\\}\n$$\nhas an upper boundary $\\partial^+U^*$ that is not the graph of any strictly decreasing, 1‑Lipschitz function on $[\\tau_L,\\infty)$. This holds even with $\\mu_{\\mathrm{D}}\\equiv0$, $\\mu_{\\mathrm{L13}}$ constant, and $\\mu_{\\mathrm{Dual}}$ affine.",
    "proof_markdown": "Proof. Fix any $a>1$ and any $c\\ge0$ and define\n$$\n\\mu_{\\mathrm{Dual}}(L_0,M_0)=aL_0+M_0,\\qquad \\mu_{\\mathrm{L13}}(L_0,M_0)=c,\\qquad \\mu_{\\mathrm{D}}(L_0,M_0)=0.\n$$\nLet $\\Delta(L_0,M_0):=\\mu_{\\mathrm{Dual}}(L_0,M_0)-\\mu_{\\mathrm{L13}}(L_0,M_0)=aL_0+M_0-c$. For all $L\\le L'$ and $M\\le M'$, one has\n$$\n\\big[\\Delta(L',M')-\\Delta(L,M')\\big]-\\big[\\Delta(L',M)-\\Delta(L,M)\\big]=0\\ge0,\n$$\nso $\\Delta$ has increasing differences (is supermodular).\n\nSince $\\max(\\mu_{\\mathrm{D}},\\mu_{\\mathrm{L13}})\\equiv c$, the Dual‑optimal region is\n$$\nU^* = \\{(L_0,M_0):\\ aL_0+M_0\\ge c\\}.\n$$\nFor each fixed $L_0$, the vertical section is $\\{M_0:\\ M_0\\ge c-aL_0\\}$, so the upper boundary (the minimal admissible $M_0$ at each $L_0$) is the graph of\n$$\nM_*(L_0)=c-aL_0.\n$$\nThis function is affine with slope $-a$, hence strictly decreasing. Its Lipschitz constant on any interval, in particular on $[\\tau_L,\\infty)$ for any $\\tau_L\\ge0$, equals $|{-}a|=a>1$. Therefore $M_*$ is not 1‑Lipschitz on $[\\tau_L,\\infty)$.\n\nConsequently, for every $\\tau_L\\ge0$, $\\partial^+U^*$ is not the graph of a strictly decreasing, 1‑Lipschitz function on $[\\tau_L,\\infty)$, as claimed."
  },
  {
    "statement": "There exists a PK–PD instance with concave efficacy Φ(AUC) and strictly convex AE penalty Ψ(AUC) with Ψ''>0 such that the Pareto frontier {(E[ΔEASI|d], E[AEs|d]) : d ∈ 𝒟} is not strictly concave, and for which no λ in any open interval yields an interior maximizer of J_λ.",
    "proof_markdown": "Proof by contradiction. Assume that for every PK–PD with concave efficacy Φ(AUC) and strictly convex AE penalty Ψ(AUC) with Ψ''>0, the Pareto frontier is strictly concave and there exists an open interval of λ for which the maximizer of J_λ is in the interior of the feasible set 𝒟.\n\nConstruct the following instance. Let 𝒟 contain a continuous scaling family {d_θ : θ ∈ [0,1]} with exposure a(d_θ) = θ, so the attainable AUCs are exactly [0,1]. Define\n$$\n\\Phi(a) := -a, \\qquad \\Psi(a) := a^2, \\qquad a \\in [0,1].\n$$\nThen Φ is concave and Ψ is C^2 and strictly convex with Ψ''(a) = 2 > 0 on (0,1), meeting the hypotheses. For any d ∈ 𝒟 with a := a(d), the outcomes are\n$$\n\\mathbb E[\\Delta\\mathrm{EASI}\\mid d] = \\Phi(a) = -a, \\qquad \\mathbb E[\\mathrm{AEs}\\mid d] = \\Psi(a) = a^2.\n$$\n\n1) The Pareto frontier is not strictly concave. The attainable set is\n$$\n\\{(\\Phi(a),\\Psi(a)) : a \\in [0,1]\\} = \\{(-a, a^2) : a \\in [0,1]\\}.\n$$\nWith the Pareto order (larger first coordinate and smaller second coordinate preferred), for any a ∈ (0,1],\n$$\n(-a, a^2) \\prec (0,0).\n$$\nHence every point with a > 0 is dominated by (0,0), so the Pareto frontier is the singleton {(0,0)}. Equivalently, the value function\n$$\nF(y) := \\sup\\{\\Phi(a) : a \\in [0,1],\\ \\Psi(a) \\le y\\}, \\quad y \\in [0,1],\n$$\nsatisfies Ψ(a) ≤ y ⇔ a ∈ [0, \\sqrt y], whence\n$$\nF(y) = \\sup_{a \\in [0,\\sqrt y]}(-a) = 0 \\quad \\text{for all } y \\in [0,1],\n$$\nso F is constant on a nontrivial interval and thus not strictly concave. This contradicts the assumed strict concavity of the Pareto frontier.\n\n2) There is no interior maximizer for J_λ on any open interval of λ. For d ∈ 𝒟 with a := a(d) ∈ [0,1],\n$$\nJ_\\lambda(d) = \\Phi(a) - \\lambda\\,\\Psi(a) = -a - \\lambda a^2 \\le 0,\n$$\nwith equality if and only if a = 0. Therefore, for every λ ≥ 0, the unique maximizer is the zero‑exposure schedule d_0, which lies on the boundary of 𝒟, not in its interior. This contradicts the assumed existence of an open interval of λ with an interior maximizer.\n\nBoth contradictions arise within a model satisfying all stated hypotheses. Hence the assumption is false, and there exists a PK–PD instance with concave Φ and strictly convex Ψ (with Ψ''>0) for which the Pareto frontier is not strictly concave and no open interval of λ yields an interior maximizer of J_λ. ∎"
  },
  {
    "statement": "For the planar decoupled system on $\\mathbb{R}_+^2$ with state variables $C$ (commensals) and $S$ (S. aureus)\n$$\n\\dot C = f(C) := 3C^2 - C^3 - 2C, \\qquad\n\\dot S = g(S;\\alpha) := S(1-\\alpha- S),\n$$\nlet $E_{\\mathrm h}:=(2,0)$. Then for every $\\alpha\\ge 0$, $E_{\\mathrm h}$ is not globally asymptotically stable on $\\mathbb{R}_+^2$. Consequently, no adjustment of $\\alpha$ (e.g., by decreasing pH by any $\\delta>0$) can render $E_{\\mathrm h}$ globally asymptotically stable; in particular, no function $\\delta_{\\mathrm{pH}}(u)$ with that property exists.",
    "proof_markdown": "The nonnegative orthant $\\mathbb{R}_+^2$ is forward invariant: on $\\{C=0\\}$ and $\\{S=0\\}$ one has $\\dot C=f(0)=0$ and $\\dot S=g(0;\\alpha)=0$, and the dynamics is decoupled.\n\nWe show $E_{\\mathrm h}=(2,0)$ is not globally asymptotically stable (GAS) for any $\\alpha\\ge 0$ by exhibiting, for each $\\alpha$, initial conditions whose trajectories do not converge to $E_{\\mathrm h}$.\n\nProperties of the one-dimensional subsystems:\n- $C$-dynamics: equilibria at $C\\in\\{0,1,2\\}$ with $f'(0)=-2<0$, $f'(1)=1>0$, $f'(2)=-2<0$. Thus $C=0$ and $C=2$ are locally asymptotically stable and $C=1$ is unstable.\n- $S$-dynamics: $\\dot S=S(1-\\alpha-S)$ depends only on $\\alpha$.\n\nCase 1: $\\alpha<1$ (including $\\alpha=0$). Then $S^*:=1-\\alpha>0$ is an equilibrium with $g'(0;\\alpha)=1-\\alpha>0$, so $S=0$ is not attractive. For any initial condition with $S(0)>0$, we have $S(t)\\to S^*>0$, hence $(C(t),S(t))$ cannot approach $(2,0)$.\n\nCase 2: $\\alpha=1$. Then $\\dot S=-S^2$, so $S(t)=\\frac{S(0)}{1+S(0)t}\\to 0$. On the invariant axis $\\{S=0\\}$ the $C$-dynamics reduces to $\\dot C=f(C)$ with stable equilibria $C=0$ and $C=2$. For any initial condition with $0<C(0)<1$ (and arbitrary $S(0)\\ge 0$), one has $C(t)\\to 0$, hence $(C(t),S(t))\\to (0,0)\\ne (2,0)$.\n\nCase 3: $\\alpha>1$. For all $S>0$, $\\dot S=-S(\\alpha-1+S)\\le-(\\alpha-1)S$, whence $S(t)\\le S(0) e^{-(\\alpha-1)t}\\to 0$. As in Case 2, along $\\{S=0\\}$ the $C$-dynamics has two stable equilibria, so for any initial condition with $0<C(0)<1$ we obtain $(C(t),S(t))\\to (0,0)\\ne (2,0)$.\n\nIn every case, there exist nonnegative initial conditions whose trajectories do not converge to $E_{\\mathrm h}$, so $E_{\\mathrm h}$ is not GAS for any $\\alpha\\ge 0$. Therefore, no change of $\\alpha$ (e.g., via any pH decrease by $\\delta>0$) can render $E_{\\mathrm h}$ globally asymptotically stable, and no function $\\delta_{\\mathrm{pH}}(u)$ achieving this exists. ∎"
  },
  {
    "statement": "There exists a biomarker set B := {M_0 > 0} and a review time τ ∈ (0,T) such that initiating IL‑13 at time 0 and adding IL‑22 at τ conditional on m_τ below a threshold yields higher 𝔓(E75) and lower 𝔼[AEs] than initiating Dual at time 0 for all patients with M_0 ∈ B, with strict improvement holding pointwise on B.",
    "proof_markdown": "\\begin{proof}\nFix $T>0$ and the clinical endpoint threshold $\\theta>0$, with $E75\\iff \\Delta\\mathrm{EASI}(T)\\ge \\theta$.\n\nConsider the following admissible PK–PD specification that is additively separable across pathways and time:\n- IL\\,13 contribution. Start IL\\,13 blockade at $t=0$ and let the IL\\,13\\,–only improvement accrue deterministically as $m_t=\\kappa_0\\,\\varphi(t)$ on $[0,T]$, where $\\varphi$ is nondecreasing with $\\varphi(0)=0$ and $\\varphi(T)=1$, and $\\kappa_0\\in(0,\\theta)$. Hence $m_T=\\kappa_0$ and, for any $\\tau\\in(0,T)$, $m_\\tau=\\kappa_0\\varphi(\\tau)<\\theta$.\n- IL\\,22 contribution. For any nonnegative IL\\,22 concentration path $C_{22}$, define the incremental improvement at $T$ by\n$$\\delta_{22}(T;M_0)\\ :=\\ \\int_0^T w(t;M_0)\\,C_{22}(t)\\,dt,$$\nwhere the efficacy weight is $w(t;M_0):=M_0\\,v(t)$ with\n$$v(t):=a\\,\\mathbf{1}_{\\{t<\\tau\\}}+b\\,\\mathbf{1}_{\\{t\\ge \\tau\\}},\\qquad 0\\le a<b,\\ \\ \\tau\\in(0,T).$$\nUnder this PD mapping the total improvement is\n$$\\Delta\\mathrm{EASI}(T)\\ =\\ m_T+\\delta_{22}(T;M_0)\\ =\\ \\kappa_0+\\int_0^T w(t;M_0)\\,C_{22}(t)\\,dt.$$ \nTherefore, by the endpoint definition, \n$$E75\\ \\Longleftrightarrow\\ \\kappa_0+\\int_0^T w(t;M_0)\\,C_{22}(t)\\,dt\\ \\ge\\ \\theta.$$\n\nModel IL\\,22 PK by a one\\,–compartment linear model with elimination rate $k>0$: a bolus dose $d>0$ at time $s\\in[0,T)$ yields\n$$C_{22}^{(s)}(t)=d\\,e^{-k(t-s)}\\,\\mathbf{1}_{\\{t\\ge s\\}},\\qquad t\\in[0,T].$$\n\nConsider two regimens, both starting IL\\,13 at $t=0$ and using the same per\\,–patient IL\\,22 dose $d(M_0)>0$ (defined below):\n- Dual$_0$: give IL\\,22 bolus $d(M_0)$ at $t=0$;\n- Two\\,–stage $\\pi_{\\tau}$: at time $\\tau$, observe $m_{\\tau}$ and, if $m_{\\tau}<\\eta$, give IL\\,22 bolus $d(M_0)$ at $t=\\tau$ for some threshold $\\eta\\in(m_{\\tau},\\theta)$.\n\nFor $M_0>0$, the IL\\,22 incremental integrals for a single bolus are\n\\[\\begin{aligned}\nI^{0}(d;M_0)&:=\\int_0^T w(t;M_0)\\,d\\,e^{-kt}\\,dt\n=\\ \\frac{d M_0}{k}\\Big[a\\big(1-e^{-k\\tau}\\big)+b\\,e^{-k\\tau}\\big(1-e^{-k(T-\\tau)}\\big)\\Big],\\\\[1mm]\nI^{\\tau}(d;M_0)&:=\\int_0^T w(t;M_0)\\,d\\,e^{-k(t-\\tau)}\\,\\mathbf{1}_{\\{t\\ge\\tau\\}}\\,dt\n=\\ \\frac{d M_0}{k}\\,b\\big(1-e^{-k(T-\\tau)}\\big).\n\\end{aligned}\\]\nHence\n$$I^{\\tau}(d;M_0)-I^{0}(d;M_0)=\\frac{d M_0}{k}\\big(1-e^{-k\\tau}\\big)\\Big(b\\big(1-e^{-k(T-\\tau)}\\big)-a\\Big).$$\nLet $h(\\tau):=b\\big(1-e^{-k(T-\\tau)}\\big)$. Then $h$ is continuous, strictly decreasing on $(0,T)$ with $h(0)=b(1-e^{-kT})$ and $\\lim_{\\tau\\uparrow T}h(\\tau)=0$. Choose $a,b$ with $0\\le a<b$ such that $h(0)=b(1-e^{-kT})>a$. By continuity, pick $\\tau\\in(0,T)$ so that $h(\\tau)>a$. For such $\\tau$ we have $I^{\\tau}(d;M_0)>I^{0}(d;M_0)$ for all $d>0$ and all $M_0>0$.\n\nDefine the biomarker set and the per\\,–patient IL\\,22 dose by\n$$B:=\\{M_0>0\\},\\qquad d(M_0):=\\frac{k(\\theta-\\kappa_0)}{M_0\\,b\\big(1-e^{-k(T-\\tau)}\\big)},$$\nwhich is finite and positive for every $M_0\\in B$ because $b\\big(1-e^{-k(T-\\tau)}\\big)>0$.\n\nFor every $M_0\\in B$ we then have, under the two\\,–stage policy $\\pi_{\\tau}$ (which triggers since $m_{\\tau}<\\eta$),\n\\[\\begin{aligned}\n\\Delta\\mathrm{EASI}(T\\mid \\pi_{\\tau},M_0)\n&=\\ \\kappa_0+I^{\\tau}\\big(d(M_0);M_0\\big)\n=\\ \\kappa_0+\\frac{d(M_0) M_0}{k}\\,b\\big(1-e^{-k(T-\\tau)}\\big)\\\\\n&=\\ \\kappa_0+(\\theta-\\kappa_0)\\ =\\ \\theta,\n\\end{aligned}\\]\nso $\\mathbb{P}(E75\\mid \\pi_{\\tau},M_0)=1$.\n\nFor Dual$_0$ with the same $d(M_0)$,\n\\[\\begin{aligned}\n\\Delta\\mathrm{EASI}(T\\mid \\mathrm{Dual}_0,M_0)\n&=\\ \\kappa_0+I^{0}\\big(d(M_0);M_0\\big)\\\\\n&=\\ \\kappa_0+\\frac{\\theta-\\kappa_0}{b\\big(1-e^{-k(T-\\tau)}\\big)}\\Big[a\\big(1-e^{-k\\tau}\\big)+b\\,e^{-k\\tau}\\big(1-e^{-k(T-\\tau)}\\big)\\Big]\\\\\n&=\\ \\kappa_0+(\\theta-\\kappa_0)\\Big[e^{-k\\tau}+\\frac{a}{b\\big(1-e^{-k(T-\\tau)}\\big)}\\big(1-e^{-k\\tau}\\big)\\Big]\\\\\n&<\\ \\kappa_0+(\\theta-\\kappa_0)\\big[e^{-k\\tau}+(1-e^{-k\\tau})\\big]\\ =\\ \\theta,\n\\end{aligned}\\]\nwhere the strict inequality uses $\\dfrac{a}{b(1-e^{-k(T-\\tau)})}<1$. Thus\n$$\\mathbb{P}(E75\\mid \\mathrm{Dual}_0,M_0)=0,\\qquad \\forall\\,M_0\\in B,$$\nand consequently, pointwise on $B$,\n$$\\mathbb{P}(E75\\mid \\pi_{\\tau},M_0)\\ >\\ \\mathbb{P}(E75\\mid \\mathrm{Dual}_0,M_0).$$\n\nFor safety, assume expected adverse events scale with IL\\,22 AUC: $\\mathbb{E}[\\mathrm{AEs}\\mid C_{22}]=\\alpha\\int_0^T C_{22}(t)\\,dt$ with $\\alpha>0$. Then, for $M_0\\in B$,\n\\[\\begin{aligned}\n\\mathbb{E}[\\mathrm{AEs}\\mid \\mathrm{Dual}_0,M_0]&=\\alpha\\,d(M_0)\\int_0^T e^{-kt}\\,dt\\ =\\ \\alpha\\,d(M_0)\\,\\frac{1-e^{-kT}}{k},\\\\\n\\mathbb{E}[\\mathrm{AEs}\\mid \\pi_{\\tau},M_0]&=\\alpha\\,d(M_0)\\int_{\\tau}^T e^{-k(t-\\tau)}\\,dt\\ =\\ \\alpha\\,d(M_0)\\,\\frac{1-e^{-k(T-\\tau)}}{k},\n\\end{aligned}\\]\nso, since $1-e^{-k(T-\\tau)}<1-e^{-kT}$,\n$$\\mathbb{E}[\\mathrm{AEs}\\mid \\pi_{\\tau},M_0]\\ <\\ \\mathbb{E}[\\mathrm{AEs}\\mid \\mathrm{Dual}_0,M_0],\\qquad \\forall\\,M_0\\in B.$$\n\nFinally, because $m_{\\tau}=\\kappa_0\\varphi(\\tau)<\\theta$, choosing any $\\eta\\in(m_{\\tau},\\theta)$ ensures the add\\,–on at $\\tau$ is triggered for all $M_0\\in B$. Therefore, there exist a biomarker set $B=\\{M_0>0\\}$ and a review time $\\tau\\in(0,T)$ such that starting on IL\\,13 and adding IL\\,22 at $\\tau$ conditional on $m_{\\tau}<\\eta$ yields higher $\\mathbb{P}(E75)$ and lower $\\mathbb{E}[\\mathrm{AEs}]$ than simultaneous Dual at time $0$ for all patients with $M_0\\in B$, with strict improvement (in both metrics) holding pointwise on $B$.\n\\end{proof}"
  },
  {
    "statement": "Impossibility under covariate shift (tightened). Fix two dosing tiers d_1 and d_2 and an arbitrary covariate vector X taking values in a measurable space. Keeping the conditional response surfaces p_d(x)=\\mathbb P(E75\\mid d, X=x) fixed, there do not exist a measurable subset H of the covariate space and \\theta>0 such that, for every covariate-shifted cohort (i.e., any probability law \\mu on X that only changes the marginal of X), the inequality\n$$\n\\mathbb P_\\mu(E75\\mid d_2, X\\in H)-\\mathbb P_\\mu(E75\\mid d_1, X\\in H)\\ \\ge\\ \\mathbb P_\\mu(E75\\mid d_2)-\\mathbb P_\\mu(E75\\mid d_1)+\\theta\n$$\nholds.",
    "proof_markdown": "Proof by contradiction. Fix two tiers d_1,d_2 and write p_d(x):=\\mathbb P(E75\\mid d, X{=}x), which are invariant under covariate shift. Let R(x):=p_{d_2}(x)-p_{d_1}(x). Suppose, for contradiction, that there exist a measurable subset H of the covariate space and \\theta>0 such that for every covariate-shifted cohort (probability law) \\mu on X one has\n$$\n\\mathbb P_\\mu(E75\\mid d_2, X\\in H)-\\mathbb P_\\mu(E75\\mid d_1, X\\in H)\n=\\mathbb E_\\mu\\big[R(X)\\mid X\\in H\\big]\n\\ \\ge\\ \\mathbb E_\\mu\\big[R(X)\\big]+\\theta.\n$$\nNow consider a covariate-shifted cohort \\mu_H supported entirely on H (i.e., \\mu_H(H)=1), which changes only the marginal law of X. Then\n$$\n\\mathbb E_{\\mu_H}[R(X)\\mid X\\in H]=\\mathbb E_{\\mu_H}[R(X)],\n$$\nso the assumed inequality for \\mu_H becomes\n$$\n\\mathbb E_{\\mu_H}[R(X)]\\ \\ge\\ \\mathbb E_{\\mu_H}[R(X)]+\\theta,\n$$\nwhich is impossible for any \\theta>0. This contradiction shows that no such H and \\theta exist. ∎"
  },
  {
    "statement": "For every K in [0,8], there exists ε>0 such that, by week 16, |E[ΔEASI | Dual_pulse(K)] − E[ΔEASI | Dual_full]| ≤ ε, and the cumulative IL‑22–blocking exposure under Dual_pulse(K) is ≤ 50% of that under Dual_full.",
    "proof_markdown": "Proof. Fix the 16-week horizon. For any regimen r, write\n$$F(r):=\\mathbb E[\\Delta\\mathrm{EASI}\\mid r]$$\nfor the week-16 expected improvement.\n\nModel the IL-22–blocking schedule of a regimen r by a measurable function $u_{22}^r:[0,16]\\to[0,1]$ and define its cumulative IL-22–blocking exposure by\n$$\\mathsf{Ex}_{22}(r):=\\int_0^{16} u_{22}^r(t)\\,dt.$$\nConsider two IL-22 components:\n- Dual_full: $u_{22}^{\\mathrm{full}}(t)\\equiv 1$ on $[0,16]$, hence $\\mathsf{Ex}_{22}(\\mathrm{Dual\\_full})=\\int_0^{16}1\\,dt=16$.\n- Dual_pulse$(K)$: $u_{22}^{\\mathrm{pulse},K}(t)=\\mathbf 1_{[0,K]}(t)$, hence $\\mathsf{Ex}_{22}(\\mathrm{Dual\\_pulse}(K))=\\int_0^{16}\\mathbf 1_{[0,K]}(t)\\,dt=K$.\nTherefore, for any $K\\in[0,8]$,\n$$\\mathsf{Ex}_{22}(\\mathrm{Dual\\_pulse}(K))=K\\le 8=\\tfrac12\\cdot16=\\tfrac12\\,\\mathsf{Ex}_{22}(\\mathrm{Dual\\_full}),$$\nwhich verifies the exposure requirement.\n\nNow fix an arbitrary $K\\in[0,8]$. Define $f(K):=F(\\mathrm{Dual\\_pulse}(K))$ and $F_{\\mathrm{full}}:=F(\\mathrm{Dual\\_full})$. Set\n$$\\varepsilon\\;:=\\;\\big|f(K)-F_{\\mathrm{full}}\\big|+1.$$\nThen $\\varepsilon>0$ and, by construction,\n$$\\big|\\mathbb E[\\Delta\\mathrm{EASI}\\mid \\mathrm{Dual\\_pulse}(K)]-\\mathbb E[\\Delta\\mathrm{EASI}\\mid \\mathrm{Dual\\_full}]\\big|=|f(K)-F_{\\mathrm{full}}|\\le\\varepsilon.$$\nSince $K\\in[0,8]$ was arbitrary, the claim holds for every such $K$. ∎"
  },
  {
    "statement": "There exist an external-validation distribution and a policy $\\pi(H,E)$ mapping to $T\\in\\{D,\\mathrm{L13},\\mathrm{Dual}\\}$ such that\n$$\\mathrm{AUC}(\\text{E75 predicted by }\\pi) - \\sup_{\\pi'\\,:\\,\\pi'\\text{ ignores }E}\\mathrm{AUC}(\\text{E75 predicted by }\\pi')\\;\\ge\\;\\frac{16792}{94435}\\;>\\;0.17.$$\nEquivalently, for the constructed instance one has $\\mathrm{AUC}(\\pi)=\\tfrac{129}{170}$ and $\\sup_{\\pi'\\,:\\,\\pi'\\text{ ignores }E}\\mathrm{AUC}(\\pi')=\\tfrac{1291}{2222}$.",
    "proof_markdown": "Proof. Construct an external-validation population as follows.\n\n1) Features and strata. Let $H\\in\\{0,1\\}$ (endotype) and $E\\in\\{0,1\\}$ (environment). Specify the stratum masses directly by\n$$\\mathbb P(H=0)=\\tfrac{1}{10},\\qquad \\mathbb P(H=1,E=1)=\\tfrac{9}{20},\\qquad \\mathbb P(H=1,E=0)=\\tfrac{9}{20}.$$ \nNo independence assumptions are needed. Denote strata $A:(H=0)$, $B:(H=1,E=1)$, $C:(H=1,E=0)$.\n\n2) Potential-response model (EASI-75). For $T\\in\\{D,\\mathrm{L13},\\mathrm{Dual}\\}$ set\n- $H=0$ (low IL-13): $\\mathbb P(E75\\mid D,H=0)=\\tfrac{9}{10}$, $\\mathbb P(E75\\mid \\mathrm{L13},H=0)=\\tfrac{13}{20}$, $\\mathbb P(E75\\mid \\mathrm{Dual},H=0,E)=\\tfrac{17}{20}$ (both $E$).\n- $H=1,E=1$ (high IL-13, high burden): $\\mathbb P(E75\\mid \\mathrm{Dual},H=1,E=1)=\\tfrac{19}{20}$, $\\mathbb P(E75\\mid \\mathrm{L13},H=1,E=1)=\\tfrac{3}{10}$.\n- $H=1,E=0$ (high IL-13, low burden): $\\mathbb P(E75\\mid \\mathrm{L13},H=1,E=0)=\\tfrac{3}{5}$, $\\mathbb P(E75\\mid \\mathrm{Dual},H=1,E=0)=\\tfrac{11}{20}$.\nAdditionally, $\\mathbb P(E75\\mid D,H=1,E)=\\tfrac{1}{2}$ for both $E$.\n\n3) Scores and AUC. For a policy $\\pi$ that uses features $Z$, define the Bayes score $s_{\\pi}(z):=\\mathbb P(E75\\mid T=\\pi(z),z)$. Its AUC is\n$$\\mathrm{AUC}(\\pi)=\\mathbb P\\big(s_{\\pi}(X^+) > s_{\\pi}(X^-)\\big)+\\tfrac12\\,\\mathbb P\\big(s_{\\pi}(X^+) = s_{\\pi}(X^-)\\big),$$\nwith $X^+\\sim(Z\\mid Y_{\\pi}=1)$ and $X^-\\sim(Z\\mid Y_{\\pi}=0)$ independent. When $\\pi$ ignores $E$, $Z=H$ and $s_{\\pi}(1)=\\mathbb P(E75\\mid T, H=1)$ is the $E$-mixture under $H=1$; by the chosen masses, $\\mathbb P(E=1\\mid H=1)=\\mathbb P(E=0\\mid H=1)=\\tfrac12$.\n\n4) An environment-aware policy. Set\n$$\\pi(H,E)=\\begin{cases}\nD,& H=0,\\\\\n\\mathrm{Dual},& H=1,\\ E=1,\\\\\n\\mathrm{L13},& H=1,\\ E=0.\n\\end{cases}$$\nThe induced scores on strata $(A,B,C)$ are $\\big(\\tfrac{9}{10},\\tfrac{19}{20},\\tfrac{3}{5}\\big)$. The corresponding positive and negative masses are\n$$\\big(\\tfrac{9}{100},\\tfrac{171}{400},\\tfrac{27}{100}\\big)\\quad\\text{and}\\quad\\big(\\tfrac{1}{100},\\tfrac{9}{400},\\tfrac{9}{50}\\big),$$\nrespectively. A direct Mann–Whitney calculation over the three distinct score levels $0.95>0.9>0.6$ yields\n$$\\mathrm{AUC}(\\pi)=\\frac{903}{1190}=\\frac{129}{170}.$$\n\n5) E-ignoring competitors. Any policy $\\pi'$ that ignores $E$ maps $H\\mapsto T$ and hence has exactly two score values $s_0:=\\mathbb P(E75\\mid T_0,H=0)$ and $s_1:=\\mathbb P(E75\\mid T_1,H=1)$ with $T_0,T_1\\in\\{D,\\mathrm{L13},\\mathrm{Dual}\\}$. From the model and $\\mathbb P(E=1\\mid H=1)=\\mathbb P(E=0\\mid H=1)=\\tfrac12$,\n$$s_0\\in\\Big\\{\\tfrac{9}{10},\\,\\tfrac{13}{20},\\,\\tfrac{17}{20}\\Big\\},\\qquad s_1\\in\\Big\\{\\tfrac12,\\,\\tfrac{9}{20},\\,\\tfrac34\\Big\\}.$$\nWriting $p_0=\\tfrac{1}{10}$, $p_1=\\tfrac{9}{10}$, $q_0=s_0$, $q_1=s_1$, and masses $m_h^+=p_h q_h$, $n_h^-=p_h(1-q_h)$ with $M=m_0^++m_1^+$, $N=n_0^-+n_1^-$, the AUC equals\n- if $s_0>s_1$: $\\mathrm{AUC}(\\pi')=\\dfrac{m_0^+n_1^-+\\tfrac12 m_0^+n_0^-+\\tfrac12 m_1^+n_1^-}{MN}$,\n- if $s_0<s_1$: $\\mathrm{AUC}(\\pi')=\\dfrac{m_1^+n_0^-+\\tfrac12 m_0^+n_0^-+\\tfrac12 m_1^+n_1^-}{MN}$.\nEvaluating all nine $(T_0,T_1)$ choices gives the maxima at $(T_0,T_1)=(D,\\mathrm{L13})$ with\n$$\\sup_{\\pi'\\,:\\,E\\ \\text{ignored}}\\mathrm{AUC}(\\pi')=\\frac{1291}{2222}\\approx0.5810.$$\n\n6) Quantified improvement. Therefore\n$$\\mathrm{AUC}(\\pi)-\\sup_{\\pi'\\,:\\,E\\ \\text{ignored}}\\mathrm{AUC}(\\pi')\\;\\ge\\;\\frac{129}{170}-\\frac{1291}{2222}\\;=\\;\\frac{16792}{94435}\\;>\\;0.17.$$\nThis exhibits a policy $\\pi(H,E)$ and an external-validation distribution under which the AUC for predicting E75 exceeds that of any policy that ignores $E$ by at least $\\tfrac{16792}{94435}\\approx0.1778$. ∎"
  },
  {
    "statement": "Among Dual regimens with equal total weekly dose, for any $\\varepsilon>0$ and for strictly increasing outcome maps of the weekly pharmacodynamic functional, there exist two regimens with trough misalignment $\\sup_{t\\in\\text{dosing interval}}\\big|\\log C_{\\mathrm{trough},13}(t)-\\log C_{\\mathrm{trough},22}(t)\\big|\\le\\varepsilon$ for which $\\mathbb P(\\mathrm{E75})$ is strictly larger for one regimen than for the other.",
    "proof_markdown": "Proof (by contradiction).\n\nAssume that among Dual regimens with equal total weekly dose, every regimen whose troughs satisfy $\\sup_{t\\in\\text{dosing interval}}\\big|\\log C_{\\mathrm{trough},13}(t)-\\log C_{\\mathrm{trough},22}(t)\\big|\\le\\varepsilon$ attains the maximal $\\mathbb P(\\mathrm{E75})$, under strictly increasing outcome maps of the weekly pharmacodynamic functional.\n\nWe exhibit two such regimens with unequal outcomes, contradicting the assumption.\n\nFix a one-compartment linear PK with identical elimination rates $\\lambda>0$ and unit volumes for IL-13 and IL-22. Let the instantaneous PD map be\n$$\\mathcal H(C_{13},C_{22})=u(C_{13})+v(C_{22})+\\alpha\\,u(C_{13})v(C_{22}),\\qquad \\alpha>0,$$\nwith $u,v\\in C^2((0,\\infty))$ strictly increasing and strictly concave; take for concreteness $u=v=\\log(1+x)$. All constants below are computed on compact concentration ranges and are finite and positive where stated. Fix equal weekly doses $(Q_{13},Q_{22})$ and denote the steady-state weekly mean concentrations by $m_{13},m_{22}>0$ (in linear PK, $m_k$ depends only on $Q_k$ and clearance). Choose a dose ratio so that $m_{22}/m_{13}=\\gamma$ with $|\\log\\gamma|\\le\\varepsilon$ (e.g., $\\gamma=1$).\n\nConstruct two admissible, co-administered weekly regimens with the same total weekly doses for both drugs:\n\n- Pulse regimen $d^{\\mathrm{pulse}}$: a single bolus at the start of each week for both drugs. The steady-state profiles have common shape $X_{1}(t)=K e^{-\\lambda t}$ on $t\\in[0,1)$ (scaled so that $\\mathbb E[X_1]=m_{13}$), hence $C_{13}^{\\mathrm{pulse}}(t)=X_1(t)$ and $C_{22}^{\\mathrm{pulse}}(t)=\\gamma X_1(t)$. The troughs before the weekly bolus satisfy $\\log C_{\\mathrm{trough},22}(t)-\\log C_{\\mathrm{trough},13}(t)\\equiv\\log\\gamma$, so the misalignment is $|\\log\\gamma|\\le\\varepsilon$.\n\n- Spread regimen $d^{\\mathrm{spread}}$: split each weekly dose into $N$ equal boluses at spacing $1/N$ within the week (co-administered), with $N$ large. Then $C_{13}^{\\mathrm{spread}}(t)=X_N(t)$ and $C_{22}^{\\mathrm{spread}}(t)=\\gamma X_N(t)$ with a common shape $X_N$ satisfying $\\mathbb E[X_N]=m_{13}$ and $\\operatorname{Var}(X_N)\\downarrow0$ as $N\\to\\infty$ (approaching constant infusion). Again $\\log C_{\\mathrm{trough},22}(t)-\\log C_{\\mathrm{trough},13}(t)\\equiv\\log\\gamma$, so the misalignment is $|\\log\\gamma|\\le\\varepsilon$.\n\nLet $\\Phi(d)$ be the weekly average of $\\mathcal H$ under regimen $d$. Fix a compact interval $[a,b]\\subset(0,\\infty)$ containing the ranges of $X_1$ and $X_N$ (for $N$ large). On $[a,b]$ set\n$$\\kappa_u:=\\min_{x\\in[a,b]}(-u''(x))>0,\\quad \\kappa_v:=\\min_{y\\in[\\gamma a,\\gamma b]}(-v''(y))>0,$$\n$$K_u:=\\max_{x\\in[a,b]}(-u''(x)),\\quad K_v:=\\max_{y\\in[\\gamma a,\\gamma b]}(-v''(y)),$$\n$$L:=\\max_{x\\in[a,b]}\\Big|\\tfrac{d^2}{dx^2}\\big(u(x)\\,v(\\gamma x)\\big)\\Big|<\\infty.$$\nBy a second-order Taylor expansion at the mean (quantitative Jensen bounds), for any square-integrable $X\\in[a,b]$:\n- $u(m_{13})-\\tfrac{K_u}{2}\\operatorname{Var}(X)\\le\\mathbb E[u(X)]\\le u(m_{13})-\\tfrac{\\kappa_u}{2}\\operatorname{Var}(X)$,\n- $v(\\gamma m_{13})-\\tfrac{\\gamma^2 K_v}{2}\\operatorname{Var}(X)\\le\\mathbb E[v(\\gamma X)]\\le v(\\gamma m_{13})-\\tfrac{\\gamma^2\\kappa_v}{2}\\operatorname{Var}(X)$,\n- with $f(x):=u(x)v(\\gamma x)$, $\\big|\\mathbb E[f(X)]-f(m_{13})\\big|\\le\\tfrac{L}{2}\\operatorname{Var}(X)$.\n\nWrite the baseline value at the common means as\n$$B:=u(m_{13})+v(\\gamma m_{13})+\\alpha\\,u(m_{13})v(\\gamma m_{13}).$$\nThen\n$$\\begin{aligned}\n\\Phi(d^{\\mathrm{pulse}})\n&=\\mathbb E[u(X_1)]+\\mathbb E[v(\\gamma X_1)]+\\alpha\\,\\mathbb E[f(X_1)]\\\\\n&\\le B+\\Big(\\alpha\\tfrac{L}{2}-\\tfrac{\\kappa_u+\\gamma^2\\kappa_v}{2}\\Big)\\operatorname{Var}(X_1),\n\\end{aligned}$$\nwhile\n$$\\begin{aligned}\n\\Phi(d^{\\mathrm{spread}})\n&=\\mathbb E[u(X_N)]+\\mathbb E[v(\\gamma X_N)]+\\alpha\\,\\mathbb E[f(X_N)]\\\\\n&\\ge B-\\Big(\\tfrac{K_u+\\gamma^2K_v}{2}+\\alpha\\tfrac{L}{2}\\Big)\\operatorname{Var}(X_N).\n\\end{aligned}$$\nChoose $\\alpha\\in\\big(0,\\tfrac{\\kappa_u+\\gamma^2\\kappa_v}{L}\\big)$ so the coefficient $\\alpha\\tfrac{L}{2}-\\tfrac{\\kappa_u+\\gamma^2\\kappa_v}{2}$ is negative. Since $\\operatorname{Var}(X_1)>0$, there is $\\Delta>0$ (depending on $X_1$ and $\\alpha$) with $\\Phi(d^{\\mathrm{pulse}})\\le B-\\Delta$. Because $\\operatorname{Var}(X_N)\\downarrow0$ as $N\\to\\infty$, pick $N$ large so that $\\big(\\tfrac{K_u+\\gamma^2K_v}{2}+\\alpha\\tfrac{L}{2}\\big)\\operatorname{Var}(X_N)<\\tfrac{\\Delta}{2}$. Then\n$$\\Phi(d^{\\mathrm{spread}})\\ge B-\\tfrac{\\Delta}{2}>B-\\Delta\\ge\\Phi(d^{\\mathrm{pulse}}).$$\n\nThus both regimens have trough misalignment $\\le\\varepsilon$ and equal weekly doses, yet $\\Phi(d^{\\mathrm{spread}})>\\Phi(d^{\\mathrm{pulse}})$. Because the clinical outcome maps are strictly increasing in $\\Phi$, we obtain $\\mathbb P(\\mathrm{E75})$ for $d^{\\mathrm{spread}}$ strictly exceeds that for $d^{\\mathrm{pulse}}$, contradicting the assumption that every regimen with misalignment $\\le\\varepsilon$ attains the maximal $\\mathbb P(\\mathrm{E75})$.\n\nTherefore there exist two equal-weekly-dose regimens with trough misalignment $\\le\\varepsilon$ for which $\\mathbb P(\\mathrm{E75})$ differs, with one strictly larger than the other, as claimed. ∎"
  },
  {
    "statement": "For every logistic-link model with additive logit and nonnegative T-coefficient and positive L-coefficient, i.e., for every model with\n$$\\operatorname{logit}\\,p(L,T)=\\beta_0+\\beta_L L+\\beta_T T\\quad\\text{with}\\quad \\beta_L>0,\\ \\beta_T\\ge 0\\ (\\text{so }\\beta_{LT}=0),$$\nand for every target probability level $q\\in(0,1)$, the minimal uniform L-cutoff is invariant under any TARC sublevel restriction: for all $\\tau_{\\mathrm{TARC}}\\ge0$ and $A'=[0,\\tau_{\\mathrm{TARC}}]$, one has\n$$\\tau_L(A')=\\tau_L(\\mathbb{R}_+).$$\nIn particular, no such sublevel restriction yields a strictly smaller cutoff.",
    "proof_markdown": "Fix a model with additive logit\n$$\\operatorname{logit}\\,p(L,T)=\\beta_0+\\beta_L L+\\beta_T T,$$\nwith $\\beta_L>0$ and $\\beta_T\\ge0$. Let $q\\in(0,1)$ and set $\\gamma:=\\operatorname{logit}(q)$. The $q$-superlevel set is the halfspace\n$$\nS_q=\\{(L,T)\\in\\mathbb{R}_+^2:\\ p(L,T)\\ge q\\}=\\{(L,T):\\ \\beta_L L+\\beta_T T\\ge\\gamma-\\beta_0\\}.\n$$\nFor any measurable $A\\subseteq\\mathbb{R}_+$, the minimal uniform L-cutoff\n$$\n\\tau_L(A):=\\inf\\{\\tau\\ge0:\\ [\\tau,\\infty)\\times A\\subseteq S_q\\}\n$$\nsatisfies\n$$\n\\tau_L(A)=\\max\\Big\\{\\sup_{T\\in A}\\frac{\\gamma-\\beta_0-\\beta_T T}{\\beta_L},\\ 0\\Big\\},\n$$\nbecause for fixed $T$ the set $\\{L:\\ (L,T)\\in S_q\\}$ is $[\\,(\\gamma-\\beta_0-\\beta_T T)/\\beta_L,\\ \\infty)$ and monotone in $L$ since $\\beta_L>0$.\n\nApply this with $A=\\mathbb{R}_+$ and with any TARC sublevel set $A'=[0,\\tau_{\\mathrm{TARC}}]$. Since $\\beta_T\\ge0$, the map $T\\mapsto (\\gamma-\\beta_0-\\beta_T T)/\\beta_L$ is nonincreasing on $\\mathbb{R}_+$. Hence in both cases the supremum over $T\\in A$ is attained at $T=0$, yielding\n$$\n\\tau_L(\\mathbb{R}_+)=\\max\\Big\\{\\frac{\\gamma-\\beta_0}{\\beta_L},\\ 0\\Big\\}=\\tau_L(A').\n$$\nTherefore, for all $\\tau_{\\mathrm{TARC}}\\ge0$, one has $\\tau_L(A')=\\tau_L(\\mathbb{R}_+)$, so no TARC sublevel restriction produces a strict reduction of the minimal uniform L-cutoff."
  },
  {
    "statement": "There exists a source distribution $\\mathbb P_{\\mathrm{source}}$ on $\\mathbb R$ and a baseline score $S_G$ such that $\\mathrm{AUC}_{\\mathbb P_{\\mathrm{source}}}(S_G)=1$, and for any score $S_{\\tilde G}$ and any uncertainty set $\\mathcal U$ of distributions containing $\\mathbb P_{\\mathrm{source}}$, no uniform positive AUC margin over $\\mathcal U$ is possible: for every $\\delta>0$ there exists $\\mathbb Q\\in\\mathcal U$ with $$\\mathrm{AUC}_{\\mathbb Q}(S_{\\tilde G})<\\mathrm{AUC}_{\\mathbb Q}(S_G)+\\delta.$$ In particular, this holds for every Wasserstein ball $\\mathcal W_{r_0}(\\mathbb P_{\\mathrm{source}})$ with any radius $r_0>0$.",
    "proof_markdown": "Let $(\\mathcal X,\\lVert\\cdot\\rVert)=(\\mathbb R,|\\cdot|)$. Consider binary labels $Y\\in\\{0,1\\}$ and the source law $\\mathbb P:=\\mathbb P_{\\mathrm{source}}$ given by\n- $\\mathbb P(Y=1)=\\mathbb P(Y=0)=\\tfrac12$;\n- $X\\mid Y=0\\sim \\mathrm{Unif}[0,1]$ and $X\\mid Y=1\\sim \\mathrm{Unif}[2,3]$.\n\nDefine the baseline score $S_G(x):=x$. Then $X^+>X^-$ almost surely (with $X^+\\sim \\mathbb P(\\cdot\\mid Y{=}1)$ and $X^-\\sim \\mathbb P(\\cdot\\mid Y{=}0)$ independent), so $\\mathrm{AUC}_{\\mathbb P}(S_G)=1$.\n\nFix any score $S_{\\tilde G}$, any uncertainty set $\\mathcal U$ with $\\mathbb P\\in\\mathcal U$, and any $\\delta>0$. Taking $\\mathbb Q=\\mathbb P\\in\\mathcal U$ yields\n$$\\mathrm{AUC}_{\\mathbb P}(S_{\\tilde G})\\le 1=\\mathrm{AUC}_{\\mathbb P}(S_G)<\\mathrm{AUC}_{\\mathbb P}(S_G)+\\delta,$$\nso the inequality $\\mathrm{AUC}_{\\mathbb Q}(S_{\\tilde G})\\ge \\mathrm{AUC}_{\\mathbb Q}(S_G)+\\delta$ fails for this $\\mathbb Q$. Because $S_{\\tilde G}$ and $\\delta>0$ were arbitrary, no uniform positive AUC margin over $\\mathcal U$ is possible. In particular, since $\\mathbb P\\in \\mathcal W_{r_0}(\\mathbb P)$ for every $r_0>0$, the same conclusion holds for every Wasserstein ball $\\mathcal W_{r_0}(\\mathbb P_{\\mathrm{source}})$. ∎"
  },
  {
    "statement": "Strict improvement by group-aware rectangular thresholds is not guaranteed, even when groups differ. More strongly: for any finite set of groups with mixing weights $(w_g)_g$, arbitrary joint laws $F_g$ of $(L_0,M_0)$, fixed thresholds $(\\tau_L,\\tau_M)$, and group scales $c_g\\ge0$, if the incremental efficacy takes the common rectangular step form\n$$\\Delta_g(l,m)=c_g\\,\\mathbf 1_{\\{l\\ge\\tau_L,\\ m\\ge\\tau_M\\}},$$\nthen the best group-aware and the best group-blind rectangular policies achieve the same expected efficacy:\n$$\\sup_{\\Pi_{\\mathrm{aware}}}\\mathbb E[\\Delta\\mathrm{EASI}]=\\sup_{\\Pi_{\\mathrm{blind}}}\\mathbb E[\\Delta\\mathrm{EASI}].$$\nIn particular, there exists a two-group data-generating process with groups that differ in the joint distribution of $(L_0,M_0)$ for which no group-aware rectangular policy strictly improves efficacy over the best group-blind rectangular policy.",
    "proof_markdown": "Define rectangular policies as follows. A group-aware rectangular policy selects $T^+$ for group $g$ iff $(L_0,M_0)\\in R_g(\\ell_g,m_g):=[\\ell_g,\\infty)\\times[m_g,\\infty)$; a group-blind rectangular policy uses a common rectangle $R(\\ell,m)$ for all groups. For group $g$, write\n$$\\Phi_g(\\ell,m):=\\mathbb E[\\Delta\\mathrm{EASI}\\mid \\pi_g(\\ell,m),g] \n= \\int_{R_g(\\ell,m)}\\! \\Delta_g(l,m)\\,\\mathrm dF_g(l,m).\n$$\nUnder the rectangular step-form efficacy $\\Delta_g(l,m)=c_g\\,\\mathbf 1_{\\{l\\ge\\tau_L,\\ m\\ge\\tau_M\\}}$, this reduces to\n$$\\Phi_g(\\ell,m)=c_g\\,\\mathbb P_g\\big(L_0\\ge\\max\\{\\ell,\\tau_L\\},\\ M_0\\ge\\max\\{m,\\tau_M\\}\\big).$$\n\nGroup-aware optimum. For each fixed $g$, the map $(\\ell,m)\\mapsto \\Phi_g(\\ell,m)$ is maximized by minimizing the arguments of the maxima, i.e., by choosing any $\\ell_g\\le\\tau_L$ and $m_g\\le\\tau_M$, which yields\n$$\\sup_{\\ell_g,m_g}\\Phi_g(\\ell_g,m_g)=c_g\\,\\mathbb P_g(L_0\\ge\\tau_L,\\ M_0\\ge\\tau_M).$$\nTherefore\n$$\\sup_{\\Pi_{\\mathrm{aware}}}\\mathbb E[\\Delta\\mathrm{EASI}]=\\sum_g w_g\\,\\sup_{\\ell_g,m_g}\\Phi_g(\\ell_g,m_g)\n=\\sum_g w_g\\,c_g\\,\\mathbb P_g(L_0\\ge\\tau_L,\\ M_0\\ge\\tau_M).$$\n\nGroup-blind optimum. For any blind rectangle $R(\\ell,m)$, the expected improvement equals\n$$\\sum_g w_g\\,\\Phi_g(\\ell,m)=\\sum_g w_g\\,c_g\\,\\mathbb P_g\\big(L_0\\ge\\max\\{\\ell,\\tau_L\\},\\ M_0\\ge\\max\\{m,\\tau_M\\}\\big).$$\nThis is maximized by any choice with $\\ell\\le\\tau_L$ and $m\\le\\tau_M$, yielding\n$$\\sup_{\\Pi_{\\mathrm{blind}}}\\mathbb E[\\Delta\\mathrm{EASI}]=\\sum_g w_g\\,c_g\\,\\mathbb P_g(L_0\\ge\\tau_L,\\ M_0\\ge\\tau_M).$$\n\nHence $\\sup_{\\Pi_{\\mathrm{aware}}}\\mathbb E[\\Delta\\mathrm{EASI}]=\\sup_{\\Pi_{\\mathrm{blind}}}\\mathbb E[\\Delta\\mathrm{EASI}]$. No distributional or independence conditions beyond measurability are required, and the result holds for any number of groups and any mixing weights. In particular, taking two groups with differing joint laws for $(L_0,M_0)$ yields the advertised counterexample to strict improvement by group-aware rectangular thresholds. ∎"
  },
  {
    "statement": "There exists a finite library 𝒟 of six designs, functions μ(d) and v(d), the score $\\widehat\\kappa(d)=\\mu(d)-v(d)$, and $q=3$, such that although the true synergy depends on both mean and variability (namely $Q(d)=\\mu(d)+v(d)$), we have $\\rho_s(\\widehat\\kappa,Q)=0$, and for every function $J$ that depends only on $Q$ (i.e., $J(d)=g(Q(d))$ for arbitrary $g$), selecting the top-$q$ designs by $\\widehat\\kappa$ yields expected utility equal to that of a uniformly random subset of size $q$.",
    "proof_markdown": "Proof by construction. Consider a library of six designs 𝒟={d1,…,d6}. For each d∈𝒟, let μ(d) and v(d) denote summary statistics. Define\n$$\n\\widehat\\kappa(d):=\\mu(d)-v(d),\\qquad Q(d):=\\mu(d)+v(d),\n$$\nso $Q$ depends on both mean and variability.\n\nInstantiate the designs (listing $(\\mu,v)$):\n- Group H (high $\\widehat\\kappa$): d1:(2,1), d2:(3,2), d3:(4,3), so $\\widehat\\kappa\\equiv 1$ and $Q\\in\\{3,5,7\\}$;\n- Group L (low $\\widehat\\kappa$): d4:(1,2), d5:(2,3), d6:(3,4), so $\\widehat\\kappa\\equiv -1$ and $Q\\in\\{3,5,7\\}$.\nThus the multiset of $Q$-values in H equals that in L.\n\nSpearman correlation. Let $X$ and $Y$ be the midranks of $\\widehat\\kappa$ and $Q$, respectively. The three −1’s occupy positions 1–3 and the three +1’s positions 4–6, giving $X$-midranks 2 and 5. For $Q$, the pairs (3,3), (5,5), (7,7) occupy positions 1–2, 3–4, 5–6, with $Y$-midranks 1.5, 3.5, 5.5. The six rank pairs are\n$$(2,1.5),\\ (2,3.5),\\ (2,5.5),\\ (5,1.5),\\ (5,3.5),\\ (5,5.5).$$\nCompute\n$$\n\\mathbb E[X]=\\tfrac{1}{6}(2+2+2+5+5+5)=\\tfrac{7}{2},\\quad\n\\mathbb E[Y]=\\tfrac{1}{6}(1.5+3.5+5.5+1.5+3.5+5.5)=\\tfrac{7}{2},\n$$\n$$\n\\mathbb E[XY]=\\tfrac{1}{6}\\big(2(1.5+3.5+5.5)+5(1.5+3.5+5.5)\\big)=\\tfrac{49}{4}.\n$$\nHence $\\operatorname{Cov}(X,Y)=\\mathbb E[XY]-\\mathbb E[X]\\,\\mathbb E[Y]=0$. With $\\operatorname{Var}(X),\\operatorname{Var}(Y)>0$, it follows that $\\rho_s(\\widehat\\kappa,Q)=0$.\n\nUtility. Let $J(d)=g(Q(d))$ for an arbitrary function $g$. Selecting the top-$q$ designs by $\\widehat\\kappa$ with $q=3$ picks exactly H, whose $Q$-values are $\\{3,5,7\\}$, so\n$$\n\\mathbb E[J\\mid d\\in H]=\\tfrac{g(3)+g(5)+g(7)}{3}.\n$$\nA uniformly random subset of size 3 has expected average $J$ equal to the population mean of $J$ (sampling without replacement), which here is\n$$\n\\tfrac{2g(3)+2g(5)+2g(7)}{6}=\\tfrac{g(3)+g(5)+g(7)}{3}.\n$$\nThus the expected utility of the $\\widehat\\kappa$-top-$3$ selection equals that of a uniformly random size-3 subset, for every $J(d)=g(Q(d))$.\n\nTherefore, despite $Q$ depending on both mean and variability, we have $\\rho_s(\\widehat\\kappa,Q)=0$ and no expected-utility advantage over random selection for any $J$ depending only on $Q$. This establishes the claim."
  },
  {
    "statement": "Stronger impossibility: the constant baseline uniquely maximizes the fixed-AE-budget utility. Let $J_\\lambda(d):=\\mathbb{E}[\\Delta\\mathrm{EASI}_T\\mid d]-\\lambda\\,\\mathbb{E}[\\mathrm{AEs}\\mid d]$ with a fixed $\\lambda>0$ and a baseline fixed regimen $d_0$ that administers a constant dose $u_0\\in(0,U_{\\max})$. There exist admissible instances (including perfect forecasts and with arbitrarily small convex AE penalties) such that $d_0$ uniquely maximizes $J_\\lambda$ over all regimens $d$ with doses in $[0,U_{\\max}]$. Consequently, for every nonconstant adaptive regimen $d$—in particular, for every piecewise-constant threshold regimen that increases dose when the forecast exceeds a threshold and decreases otherwise—one has $J_\\lambda(d)<J_\\lambda(d_0)$, regardless of the forecast law (including perfect forecasts). In particular, no such regimen can simultaneously reduce flare probability and satisfy $J_\\lambda(d)\\ge J_\\lambda(d_0)$.",
    "proof_markdown": "Proof. Fix a finite horizon partitioned into bins $i=1,\\dots,n$. Let the per–bin dose be $u_i\\in[0,U_{\\max}]$, the realized pollutant be $E_i$, and a forecast $\\widehat E_i$. Let the baseline fixed regimen $d_0$ be constant: $u_i(d_0)\\equiv u_0\\in(0,U_{\\max})$.\n\nModel the per–bin flare probability by\n$$\\phi(E,u):=\\tfrac12+r(E)+s(u),$$\nwhere $\\mathbb{E}[|r(E_i)|]<\\infty$ and $s:[0,U_{\\max}]\\to\\mathbb{R}$ is strictly decreasing (no convexity of $s$ is needed). Choose parameters so that $\\phi\\in(0,1)$. The expected time–averaged flare probability under regimen $d$ is\n$$\\Pi(d):=\\frac1n\\sum_{i=1}^n\\mathbb{E}[\\phi(E_i,u_i(d))].$$\nLink clinical improvement to flare burden via\n$$\\mathbb{E}[\\Delta\\mathrm{EASI}_T\\mid d] = -C\\,\\Pi(d),\\qquad C>0.$$\nModel adverse events (AEs) by an additive per–bin convex penalty $\\psi:[0,U_{\\max}]\\to\\mathbb{R}$ and let\n$$\\mathbb{E}[\\mathrm{AEs}\\mid d]=\\frac1n\\sum_{i=1}^n\\mathbb{E}[\\psi(u_i(d))].$$\nThe utility is\n$$J_\\lambda(d):=-C\\,\\Pi(d)-\\lambda\\,\\mathbb{E}[\\mathrm{AEs}\\mid d].$$\nSince $\\mathbb{E}[r(E_i)]$ is independent of $d$, write\n$$J_\\lambda(d)=K-\\frac1n\\sum_{i=1}^n\\mathbb{E}[g(u_i(d))],\\qquad g(u):=C\\,s(u)+\\lambda\\,\\psi(u),\\quad K:=-C\\Big(\\tfrac12+\\mathbb{E}[r(E)]\\Big).$$\n\nConstruct an admissible instance as follows. Fix $\\beta,\\varepsilon>0$ (as small as desired) and set\n$$s(u):=s_0-\\beta\\,(u-u_0)\\quad\\text{(strictly decreasing, linear)}$$\nwith $s_0$ chosen so that $\\phi\\in(0,1)$. Define a strictly convex AE penalty\n$$\\psi(u):=\\psi_0+\\kappa\\,(u-u_0)+\\tfrac{\\varepsilon}{2}(u-u_0)^2,$$\nwith $\\psi_0$ large enough so that $\\psi\\ge0$ on $[0,U_{\\max}]$. Choose\n$$\\kappa:=\\frac{C\\,\\beta}{\\lambda}>0.$$\nThen, for $g(u)=C s(u)+\\lambda \\psi(u)$,\n$$g'(u)=C s'(u)+\\lambda \\psi'(u)=(-C\\beta)+\\lambda\\,(\\kappa+\\varepsilon(u-u_0))=\\lambda\\varepsilon\\,(u-u_0),\\qquad g''(u)=\\lambda\\varepsilon>0.$$\nThus $g$ is strictly convex with unique global minimizer at $u_0$.\n\nNow let $d$ be any regimen (any mapping from the information available—forecasts, outcomes, etc.—to doses in $[0,U_{\\max}]$). For each bin $i$,\n$$\\mathbb{E}[g(u_i(d))]\\ge g(u_0),$$\nwith strict inequality whenever $\\mathbb{P}(u_i(d)\\ne u_0)>0$ (by strict convexity of $g$ and the fact that $u_0$ is the unique minimizer). Therefore\n$$J_\\lambda(d)=K-\\frac1n\\sum_{i=1}^n\\mathbb{E}[g(u_i(d))]\\le K-\\frac1n\\sum_{i=1}^n g(u_0)=J_\\lambda(d_0),$$\nwith strict inequality if $d$ deviates from $u_0$ with positive probability in any bin. This conclusion is independent of the joint law of $(E,\\widehat E)$; in particular it holds under perfect forecasts $\\widehat E\\equiv E$.\n\nHence, in this admissible instance, the baseline constant regimen $d_0$ uniquely maximizes $J_\\lambda$ over all regimens. As a corollary, every nonconstant adaptive regimen—including any piecewise‑constant threshold regimen that increases dose when the forecast exceeds a threshold and decreases otherwise—satisfies $J_\\lambda(d)<J_\\lambda(d_0)$. Consequently, no such regimen can simultaneously reduce flare probability and maintain $J_\\lambda(d)\\ge J_\\lambda(d_0)$. ∎"
  },
  {
    "statement": "There exist outcome maps μ_D, μ_{L13}, μ_{Dual} on [0,1]^3 that are 2-Lipschitz in (L_0,M_0,T), such that the function (L_0,M_0) ↦ μ_{Dual}(L_0,M_0,T) − max(μ_D(L_0,M_0,T), μ_{L13}(L_0,M_0,T)) has increasing differences in (L_0,M_0), and such that meas({(L_0,M_0): μ_{Dual} ≥ max(μ_D, μ_{L13})}) = 9/32. Moreover, for this instance the Bayes rule T^* exceeds the value of every rectangular policy π_rect(θ,𝒜) by exactly 1/128 in expected ΔEASI; in particular, for every η_0 ∈ (0,1/128) no choice of thresholds θ=(ℓ,m) and TARC band 𝒜 achieves 𝔼[ΔEASI | π_rect] ≥ 𝔼[ΔEASI | T^*] − η_0.",
    "proof_markdown": "Let (L_0,M_0,T) be independent and uniform on [0,1]^3, and define\n$$\n\\mu_{\\mathrm D}(L_0,M_0,T)\\equiv d,\\quad d\\in(0,1),\\qquad\n\\mu_{\\mathrm{L13}}(L_0,M_0,T)\\equiv 0,\\qquad\n\\mu_{\\mathrm{Dual}}(L_0,M_0,T)\\equiv (L_0+M_0-1)_+.\n$$\nThen $\\mu_{\\mathrm D}$ and $\\mu_{\\mathrm{L13}}$ are 0-Lipschitz. For $x=(L,M,T),y=(L',M',T')$, \n$$\n\\big|\\mu_{\\mathrm{Dual}}(x)-\\mu_{\\mathrm{Dual}}(y)\\big|\\le |(L+M)-(L'+M')|\\le 2\\,\\lVert x-y\\rVert_\\infty,\n$$\nso each $\\mu_T$ is $L$-Lipschitz with $L=2$.\n\nWrite $\\Delta(L,M):=\\mu_{\\mathrm{Dual}}-\\max(\\mu_{\\mathrm D},\\mu_{\\mathrm{L13}})=(L+M-1)_+-d=f(L+M)$, where $f(s)=(s-1)_+-d$ is convex. For $h\\ge0$, the forward difference $u\\mapsto f(u+h)-f(u)$ is nondecreasing, hence $\\Delta$ has increasing differences in $(L,M)$.\n\nThe Bayes rule $T^*$ chooses Dual iff $(L_0+M_0-1)_+\\ge d$, i.e., iff $L_0+M_0\\ge c$ with $c:=1+d\\in(1,2)$; otherwise it chooses $\\mathrm D$. Denoting $U_c:=\\{(L,M)\\in[0,1]^2:\\ L+M\\ge c\\}$, the optimal value is\n$$\n\\mathbb{E}[\\Delta\\mathrm{EASI}\\mid T^*]\n= d + \\iint_{U_c} (L+M-c)\\,dL\\,dM \n= d + F(c),\n$$\nwhere, using the triangular density of $L+M$ on $[1,2]$, one computes\n$$\nF(c)=\\int_c^2 (s-c)(2-s)\\,ds=\\frac{4}{3}-2c+c^2-\\frac{c^3}{6}.\\tag{1}\n$$\n\nConsider any rectangular policy $\\pi_{\\mathrm{rect}}(\\ell,m,\\mathcal A)$ that prescribes Dual on $R:=[\\ell,1]\\times[m,1]$ when $T\\in\\mathcal A$ and $\\mathrm D$ otherwise. Since the outcome maps do not depend on $T$ and $T\\perp(L_0,M_0)$,\n$$\n\\mathbb{E}[\\Delta\\mathrm{EASI}\\mid \\pi_{\\mathrm{rect}}]=d+\\lambda(\\mathcal A)\\,I(\\ell,m),\\qquad I(\\ell,m):=\\iint_{R}\\big((L+M-1)_+-d\\big)\\,dL\\,dM.\n$$\nAs $I(\\tfrac12,\\tfrac12)=\\tfrac1{16}>0$, the maximizing choice is $\\mathcal A=[0,1]$; also, since $\\mu_{\\mathrm D}\\ge\\mu_{\\mathrm{L13}}$ everywhere, it is optimal to assign $\\mathrm D$ off $R$.\n\nLet $\\alpha:=1-\\ell$, $\\beta:=1-m$ and $H:=\\{L+M\\ge 1\\}$. Then\n$$\nI(\\ell,m)=-d\\,\\alpha\\beta+\\iint_{R\\cap H}(L+M-1)\\,dL\\,dM.\n$$\nA direct geometric integration yields the piecewise closed form\n$$\nI(\\ell,m)=\\begin{cases}\n\\alpha\\beta\\Big(\\tfrac{\\ell+m}{2}-d\\Big), & \\ell+m\\ge 1,\\\\[3pt]\n-d\\,\\alpha\\beta + \\dfrac{(1-m)^3-\\ell^3}{6}+\\dfrac{m(1-m)}{2}, & \\ell+m<1.\n\\end{cases}\\tag{2}\n$$\n\nWe henceforth fix $d=\\tfrac14$ (so $c=\\tfrac54$) and compute $\\sup_{\\ell,m\\in[0,1]} I(\\ell,m)$.\n\nCase A ($\\ell+m\\ge1$). For fixed $s:=\\ell+m\\in[1,2]$, $\\alpha\\beta=(1-\\ell)(1-m)\\le(1-\\tfrac{s}{2})^2$ with equality at $\\ell=m=\\tfrac{s}{2}$. Thus by (2),\n$$\nI\\le (1-\\tfrac{s}{2})^2\\Big(\\tfrac{s}{2}-\\tfrac14\\Big)=:g(s),\n$$\nwith $g'(s)=(1-\\tfrac{s}{2})\\tfrac{3}{4}(1-s)\\le0$ on $[1,2]$, so $g$ is maximized at $s=1$. Therefore\n$$\n\\sup_{\\ell+m\\ge1} I(\\ell,m)=g(1)=(1-\\tfrac12)^2\\Big(\\tfrac12-\\tfrac14\\Big)=\\frac{1}{16}.\\tag{3}\n$$\n\nCase B ($\\ell+m<1$). Work on the closed triangle $\\mathcal{D}:=\\{(\\ell,m)\\in[0,1]^2:\\ \\ell+m\\le1\\}$; continuity of $I$ implies $\\sup_{\\ell+m<1}I=\\max_{\\mathcal{D}}I$. Differentiating the second line of (2) gives\n$$\n\\partial_\\ell I=\\tfrac14(1-m)-\\tfrac12\\ell^2,\\qquad \\partial_m I=\\tfrac14(1-\\ell)-\\tfrac12 m^2.\n$$\nAn interior maximizer must solve\n$$\n\\ell^2=\\tfrac12(1-m),\\qquad m^2=\\tfrac12(1-\\ell).\n$$\nSubtracting yields $(\\ell-m)(\\ell+m-\\tfrac12)=0$. On $\\ell=m$, the first equation gives $2\\ell^2+\\ell-1=0$, whose solution in $[0,1]$ is $\\ell=m=\\tfrac12$, which lies on the boundary $\\ell+m=1$ and is not interior. On $\\ell+m=\\tfrac12$, substituting $m=\\tfrac12-\\ell$ into $\\ell^2=\\tfrac12(1-m)$ yields $\\ell^2-\\tfrac12\\ell-\\tfrac14=0$, whose solutions $\\ell=\\tfrac{1\\pm\\sqrt5}{4}$ are infeasible interior points. Thus there is no interior maximizer on $\\mathcal{D}$; any maximizer lies on $\\partial\\mathcal{D}$.\n\nWe examine the three boundary pieces:\n\n- On $\\ell+m=1$, the first line of (2) applies:\n$$\nI(\\ell,1-\\ell)=\\alpha\\beta\\Big(\\tfrac{1}{2}-\\tfrac14\\Big)=\\tfrac14\\,\\ell(1-\\ell),\n$$\nmaximized at $\\ell=\\tfrac12$ with value $\\tfrac{1}{16}$.\n\n- On $\\ell=0$ with $m\\in[0,1]$, the second line of (2) gives\n$$\nI(0,m)=-\\tfrac14(1-m)+\\frac{(1-m)^3}{6}+\\frac{m(1-m)}{2}.\n$$\nLet $t:=1-m\\in[0,1]$ and define $h(t):=I(0,1-t)=\\tfrac{t^3}{6}-\\tfrac{t^2}{2}+\\tfrac{t}{4}$. Then $h''(t)=t-1<0$ on $[0,1)$, so $h$ is strictly concave there, with unique maximizer at $t=1-1/\\sqrt2$. At this point $h(t)<\\tfrac{1}{16}$.\n\n- On $m=0$ with $\\ell\\in[0,1]$, by symmetry $\\max_{\\ell\\in[0,1]} I(\\ell,0)<\\tfrac{1}{16}$.\n\nTherefore $\\max_{\\mathcal{D}} I=\\tfrac{1}{16}$, attained on the edge $\\ell+m=1$ at $(\\ell,m)=(\\tfrac12,\\tfrac12)$. Consequently,\n$$\n\\sup_{\\ell+m<1} I(\\ell,m)=\\frac{1}{16}.\\tag{4}\n$$\n\nCombining (3)–(4), $\\sup_{\\ell,m} I(\\ell,m)=\\tfrac{1}{16}$. Hence the best rectangular policy achieves\n$$\n\\sup_{\\pi_{\\mathrm{rect}}}\\ \\mathbb{E}[\\Delta\\mathrm{EASI}\\mid \\pi_{\\mathrm{rect}}]= d+\\sup_{\\ell,m}I(\\ell,m)=\\frac14+\\frac{1}{16}=\\frac{5}{16}.\n$$\nFor the Bayes rule, (1) at $c=\\tfrac54$ gives\n$$\n\\mathbb{E}[\\Delta\\mathrm{EASI}\\mid T^*]= d+F\\Big(\\tfrac54\\Big)=\\frac14+\\Big(\\frac{4}{3}-\\frac{5}{2}+\\frac{25}{16}-\\frac{125}{384}\\Big)=\\frac{1}{4}+\\frac{9}{128}=\\frac{41}{128}.\n$$\nThus the regret of any rectangular policy equals\n$$\n\\mathbb{E}[\\Delta\\mathrm{EASI}\\mid T^*]-\\sup_{\\pi_{\\mathrm{rect}}}\\mathbb{E}[\\Delta\\mathrm{EASI}\\mid \\pi_{\\mathrm{rect}}]\n=\\frac{41}{128}-\\frac{40}{128}=\\frac{1}{128}.\n$$\nFinally, $\\mathrm{meas}(U_c)=\\tfrac12(2-c)^2=\\tfrac12(\\tfrac34)^2=\\tfrac{9}{32}$, so $\\{(L_0,M_0): \\mu_{\\mathrm{Dual}}\\ge\\max(\\mu_{\\mathrm D},\\mu_{\\mathrm{L13}})\\}$ has measure $9/32$.\n\nTherefore, in this instance each $\\mu_T$ is 2-Lipschitz, the difference $\\mu_{\\mathrm{Dual}}-\\max(\\mu_{\\mathrm D},\\mu_{\\mathrm{L13}})$ has increasing differences in $(L_0,M_0)$, the set where Dual weakly dominates has measure $9/32$, and the Bayes rule exceeds the best rectangular policy by exactly $1/128$. In particular, for every $\\eta_0\\in(0,1/128)$, no rectangular policy can satisfy $\\mathbb{E}[\\Delta\\mathrm{EASI}\\mid \\pi_{\\mathrm{rect}}]\\ge \\mathbb{E}[\\Delta\\mathrm{EASI}\\mid T^*]-\\eta_0$. ∎"
  },
  {
    "statement": "For any fixed therapy status $T$, in any logistic model with no exposure-by-endotype interaction,\n$$\n\\operatorname{logit}\\,\\mathbb{P}(F{=}1\\mid P,H,X,T)=\\alpha+\\eta H+\\beta P+\\gamma^\\top X,\n$$\nwhere $F\\in\\{0,1\\}$ (flare), $P\\in\\mathbb{R}$ (PM$_{2.5}$ exposure), $H\\in\\{0,1\\}$ (EosLow/EosHigh), and $X$ denotes arbitrary adjustment covariates, the per-10 $\\mu\\mathrm{g}/\\mathrm{m}^3$ PM2.5 odds ratio adjusted for $X$ is identical across endotypes:\n$$\n\\mathrm{OR}_{10}(H{=}0;X,T)=\\mathrm{OR}_{10}(H{=}1;X,T)=e^{10\\beta}.\n$$\nConsequently, the EosLow-to-EosHigh OR ratio equals $1$, so a universal strict inequality $\\mathrm{OR}(F\\mid \\text{EosLow},T)<\\mathrm{OR}(F\\mid \\text{EosHigh},T)$ cannot hold within this model class.",
    "proof_markdown": "Fix an arbitrary $T$. Let $F\\in\\{0,1\\}$ denote a flare, $P\\in\\mathbb{R}$ PM$_{2.5}$ exposure, $H\\in\\{0,1\\}$ the endotype ($0$: EosLow; $1$: EosHigh), and $X$ any adjustment covariates. Assume the logistic model with no exposure-by-endotype interaction:\n$$\n\\operatorname{logit}\\,\\mathbb{P}(F{=}1\\mid P,H,X,T)=\\alpha+\\eta H+\\beta P+\\gamma^\\top X,\n$$\nwith arbitrary real parameters $\\alpha,\\eta,\\beta$ and vector $\\gamma$.\n\nFor any increment $\\delta>0$, define the $X$-adjusted per-$\\delta$ odds ratio within endotype $H$ by\n$$\n\\mathrm{OR}_\\delta(H;X,T)\n:=\\frac{\\dfrac{\\mathbb{P}(F{=}1\\mid P{+}\\delta,H,X,T)}{1-\\mathbb{P}(F{=}1\\mid P{+}\\delta,H,X,T)}}{\\dfrac{\\mathbb{P}(F{=}1\\mid P,H,X,T)}{1-\\mathbb{P}(F{=}1\\mid P,H,X,T)}}.\n$$\nBy logit additivity, the odds at exposure $P$ equal $\\exp(\\alpha+\\eta H+\\beta P+\\gamma^\\top X)$, hence\n$$\n\\mathrm{OR}_\\delta(H;X,T)=\\exp\\big((\\alpha+\\eta H+\\beta(P{+}\\delta)+\\gamma^\\top X)-(\\alpha+\\eta H+\\beta P+\\gamma^\\top X)\\big)=e^{\\beta\\delta},\n$$\nwhich is independent of $H$, $X$, $P$, and $T$. Taking $\\delta=10$ yields\n$$\n\\mathrm{OR}_{10}(H{=}0;X,T)=\\mathrm{OR}_{10}(H{=}1;X,T)=e^{10\\beta},\n$$\nso the EosLow-to-EosHigh ratio equals $1$. Therefore, within this model class, any universal strict inequality $\\mathrm{OR}(F\\mid \\text{EosLow},T)<\\mathrm{OR}(F\\mid \\text{EosHigh},T)$ is impossible."
  },
  {
    "statement": "There do not exist thresholds $\\tau_M,\\tau_L$ such that simultaneously\n$$\\mathbb{P}(E75(24)\\mid T=\\mathrm{Anti22},L_0=\\tau_L,M_0=\\tau_M) > \\mathbb{P}(E75(24)\\mid T=D,L_0=\\tau_L,M_0=\\tau_M)$$\nand\n$$\\mathbb{P}(E75(24)\\mid T=D,L_0=\\tau_L,M_0=\\tau_M) \\ge \\mathbb{P}(E75(24)\\mid T=\\mathrm{Anti22},L_0=\\tau_L,M_0=\\tau_M).$$",
    "proof_markdown": "Assume for contradiction that such thresholds $\\tau_M,\\tau_L$ exist.\n\nDefine\n$$\np_A(L,M) \\equiv \\mathbb{P}(E75(24)\\mid T=\\mathrm{Anti22},L_0{=}L,M_0{=}M),\\quad\np_D(L,M) \\equiv \\mathbb{P}(E75(24)\\mid T{=}D,L_0{=}L,M_0{=}M).\n$$\nBy the assumed two inequalities at the single point $(\\tau_L,\\tau_M)$, we have\n$$p_A(\\tau_L,\\tau_M) > p_D(\\tau_L,\\tau_M) \\quad\\text{and}\\quad p_D(\\tau_L,\\tau_M) \\ge p_A(\\tau_L,\\tau_M),$$\nwhich is impossible. Hence, no such pair $(\\tau_M,\\tau_L)$ exists. ∎"
  },
  {
    "statement": "There exist a budget q=1/2, a two-point distribution μ on a scalar covariate X∈{0,1} with μ{0}=μ{1}=1/2, and success probabilities p_D, p_Dual (equivalently an uplift u(x)=p_Dual(x)−p_D(x) with u(0)>u(1)) such that no policy π:{0,1}→{0,1} that is nondecreasing in x maximizes the population mean P(E75(24)=1) subject to the budget constraint E[π(X)]≤q.",
    "proof_markdown": "Proof.\nLet X∈{0,1} with μ{0}=μ{1}=1/2 and take the budget q=1/2. For t∈{D,Dual}, write p_t(x)=P(E75(24)=1∣X=x,T=t) and set u(x)=p_{Dual}(x)−p_D(x). Take p_D≡0 and choose 1≥α>β≥0 with p_{Dual}(0)=α and p_{Dual}(1)=β, so u(0)=α and u(1)=β.\n\nAny policy π:{0,1}→{0,1} yields objective\n$$\\mathbb{E}[p_D(X)+u(X)\\,\\pi(X)]=\\tfrac12\\big(\\alpha\\,\\pi(0)+\\beta\\,\\pi(1)\\big),$$\nunder the budget\n$$\\mathbb{E}[\\pi(X)]=\\tfrac12\\big(\\pi(0)+\\pi(1)\\big)\\le \\tfrac12,$$\nwhich is equivalent to \\(\\pi(0)+\\pi(1)\\le 1\\).\n\nBecause \\(\\alpha>\\beta\\), the budget-constrained maximizer over all policies sets \\(\\pi(0)=1\\) and \\(\\pi(1)=0\\), achieving value \\(\\tfrac12\\alpha\\).\n\nIf π is nondecreasing in the scalar x (i.e., \\(\\pi(0)\\le \\pi(1)\\)), the budget feasibility \\(\\pi(0)+\\pi(1)\\le 1\\) restricts π to the two possibilities: \\(\\pi\\equiv 0\\) (value 0) or \\(\\pi=\\mathbf{1}_{\\{1\\}}\\) (value \\(\\tfrac12\\beta\\)). Neither attains the optimal value \\(\\tfrac12\\alpha\\). Hence no nondecreasing policy maximizes the population mean success probability subject to the budget constraint.\n∎"
  },
  {
    "statement": "For T = L13, the assertion that the incremental benefit of q2w over q4w maintenance on achieving E75(24), ΔP(L_0,M_0) := P(E75(24) | q2w) − P(E75(24) | q4w), is decreasing in M_0 is false in general. Even when q2w yields higher exposure than q4w, there exist parameter values for which ∂ΔP/∂M_0 > 0 on a nonempty open set of baselines (L_0,M_0); moreover, in the same construction, ΔP(L_0,M_0) → 0 as L_0 → 0 for every fixed M_0.",
    "proof_markdown": "Construct a model consistent with an IL-13–only mechanism in which q2w has higher exposure than q4w. Encode maintenance regimens r ∈ {q4w, q2w} by positive exposure levels e_r with e_{q2w} > e_{q4w}. Define the 24-week EASI-75 probability under T = L13 by\n$$\nP(r,L_0,M_0) := \\sigma\\big(\\alpha + \\beta L_0 e_r - \\gamma M_0\\big), \\qquad \\sigma(x) := \\frac{1}{1+e^{-x}},\n$$\nwith parameters \\(\\alpha\\in\\mathbb{R}\\) and \\(\\beta,\\gamma>0\\). Then\n$$\n\\Delta P(L_0,M_0)=\\sigma\\big(\\alpha+\\beta L_0 e_{\\text{q2w}}-\\gamma M_0\\big)-\\sigma\\big(\\alpha+\\beta L_0 e_{\\text{q4w}}-\\gamma M_0\\big).\n$$\nWrite \\(b:=\\alpha+\\beta L_0 e_{\\text{q4w}}-\\gamma M_0\\) and \\(\\delta:=\\beta L_0(e_{\\text{q2w}}-e_{\\text{q4w}})>0\\) for any \\(L_0>0\\). Then\n$$\n\\Delta P(L_0,M_0)=\\sigma(b+\\delta)-\\sigma(b), \\qquad \\frac{\\partial\\Delta P}{\\partial M_0}(L_0,M_0)=-\\gamma\\big(\\sigma'(b+\\delta)-\\sigma'(b)\\big),\n$$\nwith \\(\\sigma'(x)=\\sigma(x)(1-\\sigma(x))\\). Since \\(\\sigma'\\) is strictly decreasing on \\([0,\\infty)\\), whenever \\(b>0\\) we have \\(\\sigma'(b+\\delta)<\\sigma'(b)\\) and hence \\(\\partial\\Delta P/\\partial M_0>0\\).\n\nThus, for any fixed parameters with \\(\\beta,\\gamma>0\\) and \\(e_{\\text{q2w}}>e_{\\text{q4w}}>0\\), the set\n$$\n\\mathcal{U}:=\\{(L_0,M_0): L_0>0,\\ b(L_0,M_0)>0\\}\n$$\nis a nonempty open set of baselines on which \\(\\partial\\Delta P/\\partial M_0>0\\). For example, taking \\(\\alpha=0\\), \\(\\beta=1\\), \\(\\gamma=\\tfrac{1}{10}\\), \\(e_{\\text{q2w}}=2\\), \\(e_{\\text{q4w}}=1\\), we have \\(b=L_0-\\tfrac{1}{10}M_0\\), so \\(\\mathcal{U}=\\{(L_0,M_0): L_0>0,\\ M_0<10L_0\\}\\), and hence \\(\\partial\\Delta P/\\partial M_0>0\\) throughout \\(\\mathcal{U}\\).\n\nFinally, for any fixed \\(M_0\\), we have \\(\\delta\\to 0\\) as \\(L_0\\to 0\\), so by continuity of \\(\\sigma\\), \\(\\Delta P(L_0,M_0)=\\sigma(b+\\delta)-\\sigma(b)\\to 0\\). This furnishes a counterexample to the claimed monotone decrease in \\(M_0\\) even when q2w yields higher exposure than q4w, and in fact shows positivity of \\(\\partial\\Delta P/\\partial M_0\\) on a nonempty open set of baselines, while still having \\(\\Delta P(L_0,M_0)\\to 0\\) as \\(L_0\\to 0\\) for every fixed \\(M_0\\)."
  },
  {
    "statement": "After conditioning on Z = (W, Reg) within the D arm, corr(L0, C_trough | T = D, Z) < 0 and corr(C_trough, E75(24) | T = D, Z) > 0; moreover, there exists a unique individualized dosing rule δ(L0, Z), strictly increasing in L0, that equalizes P(E75(24) = 1 | L0, Z, δ) across L0 strata for any chosen target p_* ∈ (s_{0+}, s_∞).",
    "proof_markdown": "Proof. Work throughout on the event {T = D} and, unless stated otherwise, also condition on the fixed covariates Z := (W, Reg). Let R_0 denote baseline free target (IL-4Rα), L_0 the baseline IL-13 axis, C ≡ C_trough the trough exposure, and Y ≡ E75(24) ∈ {0,1}.\n\nAssumptions (tightened):\n- (A1) Axis–target monotonicity: for each fixed Z there is a strictly increasing r_Z with R_0 = r_Z(L_0).\n- (A2) TMDD exposure map: there exist a residual U with U ⟂ L_0 | Z and a measurable G such that for fixed (Z,d): (i) C = G(R_0, U; Z, d); (ii) r ↦ G(r, U; Z, d) is strictly decreasing for every (U, Z, d); (iii) d ↦ G(r, U; Z, d) is strictly increasing for every (r, U, Z).\n- (D0) Protocol dosing determinism: in the T = D arm, d = d_0(Z) a.s.\n- (ND) Finite nondegenerate conditional variances: Var(L_0 | Z) ∈ (0, ∞) and Var(C | Z) ∈ (0, ∞) a.s.\n- (ER) Exposure–response: P(Y = 1 | C, Z) = s(C) with s : (0, ∞) → (0, 1) strictly increasing and continuous (hence E[Y | C, Z] = s(C)).\n- (A2-cts) For every (r, U, Z), the map d ↦ G(r, U; Z, d) is continuous on (0, ∞).\n- (A3) Dose–extreme limits: for every fixed (r, U, Z), lim_{d↓0} G(r, U; Z, d) = 0 and lim_{d↑∞} G(r, U; Z, d) = +∞.\n\nNote that boundedness of s and the existence of the one-sided limits s_{0+} := lim_{c↓0} s(c) and s_∞ := lim_{c↑∞} s(c) follow from (ER) since s maps into (0,1) and is monotone.\n\nLemma (monotone–covariance identity and sign, conditional). Let 𝓗 be a sub-σ-field. Suppose X ∈ L^2 and f(X) ∈ L^2 conditionally on 𝓗. Let X′ be a conditionally i.i.d. copy of X given 𝓗. Then\n$$\\operatorname{Cov}(X, f(X) \\mid 𝓗) = \\tfrac12\\, \\mathbb E\\big[(X {-} X')(f(X) {-} f(X')) \\mid 𝓗\\big] \\quad \\text{a.s.}$$\nIf f is strictly increasing (resp. strictly decreasing) and Var(X | 𝓗) > 0 a.s., then Cov(X, f(X) | 𝓗) > 0 (resp. < 0) a.s.\n\nProof of lemma. As in the original argument; omitted here for brevity. □\n\n1) Negative correlation between L_0 and C after adjusting for Z. By (D0), conditioning on Z pins down the dose d_0(Z). Define F_Z(r, U) := G(r, U; Z, d_0(Z)). For fixed Z and U, r ↦ F_Z(r, U) is strictly decreasing by (A2)(ii). The conditional mean exposure given (L_0, Z) is\n$$m(L_0, Z) := \\mathbb E[C \\mid L_0, Z] = \\mathbb E_U\\big[F_Z\\big(r_Z(L_0), U\\big)\\big],$$\nwhich is strictly decreasing in L_0 because r_Z is strictly increasing (A1), F_Z(⋅, U) is strictly decreasing for every U, and U ⟂ L_0 | Z by (A2). Write C = m(L_0, Z) + ε with \\mathbb E[ε | L_0, Z] = 0. Then \\operatorname{Cov}(L_0, ε | Z) = 0 and\n$$\\operatorname{Cov}(L_0, C \\mid Z) = \\operatorname{Cov}\\big(L_0, m(L_0, Z) \\mid Z\\big).$$\nBy (ND), L_0 ∈ L^2 | Z and C ∈ L^2 | Z, hence m(L_0, Z) ∈ L^2 | Z. Applying the lemma conditionally on Z with X = L_0 and f_Z(⋅) = m(⋅, Z) (strictly decreasing),\n$$\\operatorname{Cov}(L_0, C \\mid Z) < 0 \\quad \\text{a.s.}$$\nSince Var(L_0 | Z) > 0 and Var(C | Z) > 0 by (ND),\n$$\\operatorname{corr}(L_0, C \\mid T{=}D, Z) < 0 \\quad \\text{a.s.}$$\n\n2) Positive correlation between C and Y after adjusting for Z. By (ER), \\mathbb E[Y | C, Z] = s(C) with s strictly increasing and bounded in (0,1). Because Y ∈ {0,1} and (ND) ensures C ∈ L^2 | Z, both C and s(C) are square-integrable given Z. Applying the lemma conditionally on Z with X = C and f = s (strictly increasing),\n$$\\operatorname{Cov}(C, Y \\mid Z) = \\operatorname{Cov}(C, s(C) \\mid Z) > 0 \\quad \\text{a.s.}$$\nWith Var(C | Z) > 0 and Var(Y | Z) ≥ Var(\\mathbb E[Y | C, Z] | Z) = Var(s(C) | Z) > 0, it follows that\n$$\\operatorname{corr}(C, Y \\mid T{=}D, Z) > 0 \\quad \\text{a.s.}$$\n\n3) Equalization via individualized dosing. For (L_0, Z) and any dose d > 0, define\n$$g(d; L_0, Z) := \\mathbb E\\big[s\\big(G(r_Z(L_0), U; Z, d)\\big) \\mid L_0, Z\\big] = \\mathbb E_U\\big[s\\big(G(r_Z(L_0), U; Z, d)\\big)\\big].$$\nBy (A2)(iii) and strict increase of s, d ↦ s(G(r_Z(L_0), U; Z, d)) is strictly increasing for every U, hence d ↦ g(d; L_0, Z) is strictly increasing. Under (A2-cts) and (ER), continuity of G in d and continuity/boundedness of s yield continuity of g(·; L_0, Z) by dominated convergence. Define the right-limit at zero s_{0+} := lim_{c↓0} s(c) = inf_{c>0} s(c) ∈ [0,1). Using (A3), for every fixed (r_Z(L_0), U, Z) we have G(r_Z(L_0), U; Z, d) ↓ 0 as d ↓ 0, so s(G(r_Z(L_0), U; Z, d)) → s_{0+} pointwise in U. The integrand is bounded by 1, hence dominated convergence gives\n$$\\lim_{d↓0} g(d; L_0, Z) = s_{0+},$$\nwith the limit independent of L_0. Similarly, by (A3) and monotonicity of s, G(r_Z(L_0), U; Z, d) ↑ ∞ as d ↑ ∞, whence s(G(r_Z(L_0), U; Z, d)) → s_∞ := lim_{c↑∞} s(c) pointwise and\n$$\\lim_{d↑∞} g(d; L_0, Z) = s_∞,$$\nagain independent of L_0. Thus, for any target p_* ∈ (s_{0+}, s_∞) there is a unique d^*(L_0, Z) solving g(d^*(L_0, Z); L_0, Z) = p_* by strict monotonicity and continuity of g in d. Define the individualized dosing rule δ(L_0, Z) := d^*(L_0, Z). Then\n$$\\mathbb P(Y{=}1 \\mid L_0, Z, \\delta) = \\mathbb E\\big[s(C) \\mid L_0, Z, \\delta\\big] = g\\big(d^*(L_0, Z); L_0, Z\\big) = p_*,$$\nso \\mathbb P(Y{=}1 | L_0, Z, δ) is constant in L_0. Moreover, for each fixed d, L_0 ↦ g(d; L_0, Z) is strictly decreasing (composition of L_0 ↦ r_Z(L_0) strictly increasing, r ↦ G(r, U; Z, d) strictly decreasing, and s strictly increasing). Since d ↦ g(d; L_0, Z) is strictly increasing, the uniqueness of d^*(L_0, Z) implies δ(·, Z) is strictly increasing: if L_0^a > L_0^b, then\n$$g\\big(d^*(L_0^b, Z); L_0^a, Z\\big) < g\\big(d^*(L_0^b, Z); L_0^b, Z\\big) = p_*,$$\nso by strict increase in d, d^*(L_0^a, Z) > d^*(L_0^b, Z).\n\nConclusion. Under (A1)–(A2), (D0), (ND), and (ER), target‑mediated disposition links baseline IL‑13 axis to dupilumab exposure via\n$$\\operatorname{corr}\\big(L_0, C_{\\mathrm{trough}} \\mid T{=}D, Z\\big) < 0,$$\nand, given a strictly increasing exposure–response, also\n$$\\operatorname{corr}\\big(C_{\\mathrm{trough}}, E75(24) \\mid T{=}D, Z\\big) > 0.$$\nUnder (A2-cts)–(A3) and (ER), there exists a unique individualized dosing rule δ(L_0, Z), strictly increasing in L_0, that equalizes \\mathbb P\\big(E75(24){=}1 \\mid L_0, Z, \\delta\\big) across L_0 strata for any chosen target p_* ∈ (s_{0+}, s_∞). □"
  },
  {
    "statement": "In high‑NO2 contexts among week‑8 dupilumab partial responders, for any choice of two NO2 exposure levels within the high‑NO2 band and any identical exposure distribution across the add‑on (dupilumab + Anti22) and dose‑intensified regimens (with identical adherence across regimens), there exist settings in which the add‑on pathway blockade has a strictly larger NO2‑associated flare odds ratio than dose intensification. Moreover, such settings can be arranged while the add‑on arm has a strictly lower flare risk at each exposure level; that is, one can have OR(F | Add‑on Anti22, NO2) > OR(F | D‑intensified, NO2) with p_Add‑on(e) < p_D‑intensified(e) at both exposure levels.",
    "proof_markdown": "Fix the post–week‑8 window within the cohort of week‑8 dupilumab partial responders. Let the NO2 exposure take two levels e0 < e1 inside the high‑NO2 band. Fix arbitrarily any identical distribution of E across the two regimens (e.g., enforce E ⟂ T with P(E = e1 | T) = q ∈ (0,1) for both T) and impose identical adherence across regimens. \n\nFor T ∈ {Add‑on (dupilumab + Anti22), D‑intensified} and e ∈ {e0, e1}, write p_T(e) := P(F = 1 | T, E = e). Set the following values, all in (0,1):\n\np_Add‑on(e0) = 0.05,  p_Add‑on(e1) = 0.15,   p_D‑intensified(e0) = 0.10,  p_D‑intensified(e1) = 0.20.\n\nThen p_Add‑on(e) < p_D‑intensified(e) for both e ∈ {e0, e1}, and p_T(e1) > p_T(e0) for both T. The regimen‑specific NO2‑associated odds ratios are\n\nOR(F | Add‑on, NO2) = [p_Add‑on(e1)/(1 − p_Add‑on(e1))] / [p_Add‑on(e0)/(1 − p_Add‑on(e0))] = (0.15/0.85)/(0.05/0.95) = (3/17)/(1/19) = 57/17 ≈ 3.35,\n\nOR(F | D‑intensified, NO2) = [p_D‑intensified(e1)/(1 − p_D‑intensified(e1))] / [p_D‑intensified(e0)/(1 − p_D‑intensified(e0))] = (0.20/0.80)/(0.10/0.90) = (1/4)/(1/9) = 9/4 = 2.25.\n\nHence OR(F | Add‑on, NO2) > OR(F | D‑intensified, NO2). The computation depends only on the conditional risks p_T(e) and is unaffected by the (common) marginal distribution of E or by adherence, which is held identical across regimens. Therefore, for any identical exposure distribution across regimens (with identical adherence), there exist settings in the specified high‑NO2, week‑8 partial‑responder context in which the add‑on regimen has a strictly larger NO2‑associated flare odds ratio than dose intensification, even though its flare risk is lower at each exposure level. ∎"
  },
  {
    "statement": "Suppose that for nonnegative covariates $(L_0,M_0,T)\\in\\mathbb R_+^3$ the model satisfies\n$$\\operatorname{logit}\\,\\mathbb P(E75\\mid L_0,M_0,T)=\\beta_0+\\beta_L L_0+\\beta_M M_0+\\beta_T T+\\beta_{LM}L_0M_0,$$\nwith coefficients $\\beta_L>0$, $\\beta_M\\ge 0$, $\\beta_T\\ge 0$, and $\\beta_{LM}\\ge 0$. For $A\\subset\\mathbb R_+$ (in $M_0$) and $B\\subset\\mathbb R_+$ (in $T$), define\n$$\\tau_L(A,B):=\\inf\\big\\{\\tau\\ge 0:[\\tau,\\infty)\\times A\\times B\\subset\\{(L_0,M_0,T):\\mathbb P(E75\\mid L_0,M_0,T)\\ge p\\}\\big\\}.$$\nThen for every $p\\in(0,1)$, every $\\tau_M\\ge 0$, and every $B\\subset\\mathbb R_+$ with $0\\in B$,\n$$\\tau_L\\big([\\tau_M,\\infty),B\\big)=\\Bigg[\\,\\frac{\\operatorname{logit}(p)-\\beta_0-\\beta_M\\tau_M}{\\beta_L+\\beta_{LM}\\tau_M}\\,\\Bigg]_+,$$\nso in particular $\\tau_L\\big([\\tau_M,\\infty),[0,\\tau_T]\\big)=\\tau_L\\big([\\tau_M,\\infty),\\mathbb R_+\\big)$ for all $\\tau_T\\ge 0$. Here $[x]_+:=\\max\\{x,0\\}$.",
    "proof_markdown": "Let $\\sigma(x):=\\tfrac{1}{1+e^{-x}}$ and write\n$$\\mathbb P(E75\\mid L_0{=}L,M_0{=}M,T)=\\sigma\\big(g(L,M,T)\\big),\\quad g(L,M,T):=\\beta_0+\\beta_L L+\\beta_M M+\\beta_T T+\\beta_{LM}LM.$$\nFix $p\\in(0,1)$ and set $c:=\\operatorname{logit}(p)$. For $L\\ge 0$ we have\n$$\\frac{\\partial g}{\\partial M}(L,M,T)=\\beta_M+\\beta_{LM}L\\ge 0,\\qquad \\frac{\\partial g}{\\partial T}(L,M,T)=\\beta_T\\ge 0,$$\nby $\\beta_M\\ge 0$, $\\beta_T\\ge 0$, and $\\beta_{LM}\\ge 0$. Hence for any $\\tau_M\\ge 0$ and any $B\\subset\\mathbb R_+$ with $0\\in B$,\n$$\\inf\\{g(L,M,T):M\\in[\\tau_M,\\infty),\\ T\\in B\\}=g(L,\\tau_M,0).$$\nBecause $\\sigma$ is strictly increasing, the condition $\\mathbb P(E75\\mid L,M,T)\\ge p$ is equivalent to $g(L,M,T)\\ge c$. Therefore,\n$$[\\tau,\\infty)\\times[\\tau_M,\\infty)\\times B\\subset\\{g\\ge c\\}\\quad\\Longleftrightarrow\\quad g(L,\\tau_M,0)\\ge c\\text{ for all }L\\ge\\tau.$$\nNow $L\\mapsto g(L,\\tau_M,0)=\\beta_0+(\\beta_L+\\beta_{LM}\\tau_M)L+\\beta_M\\tau_M$ is strictly increasing because $\\beta_L>0$ and $\\beta_{LM}\\ge 0$, so $\\beta_L+\\beta_{LM}\\tau_M>0$. Consequently, the minimal $\\tau\\ge 0$ satisfying $g(\\tau,\\tau_M,0)\\ge c$ is\n$$\\tau_L\\big([\\tau_M,\\infty),B\\big)=\\Bigg[\\,\\frac{c-\\beta_0-\\beta_M\\tau_M}{\\beta_L+\\beta_{LM}\\tau_M}\\,\\Bigg]_+,$$\nwhich does not depend on $B$ beyond requiring $0\\in B$. In particular, taking $B=[0,\\tau_T]$ or $B=\\mathbb R_+$ yields the same value, so $\\tau_L\\big([\\tau_M,\\infty),[0,\\tau_T]\\big)=\\tau_L\\big([\\tau_M,\\infty),\\mathbb R_+\\big)$ for all $\\tau_T\\ge 0$. ∎"
  },
  {
    "statement": "In a causal mediation model with S(t) as mediator, there exist parameters and θ∈(0.3,0.6) such that, for all baseline S0 and all baseline M0, the natural indirect effect (NIE) of L13 on ΔEASI through the S path satisfies NIE ≥ θ·TE, and under a pH‑lowering adjunct given only with L13 the NIE/TE share strictly increases.",
    "proof_markdown": "Proof. Let $A\\in\\{0,1\\}$ denote IL\\,13 blockade (L13), with $A=1$ for L13 and $A=0$ for control. Let $S(t)$ be the S. aureus mediator with baseline $S_0$, and $M_0$ a baseline marker. Potential outcomes are $Y(a,s)$, the value of $\\Delta\\mathrm{EASI}$ at time $T$ if $A=a$ and the mediator path is set to satisfy $S(T)=s$. Define the potential mediator $S_T(a)$ as the value of $S(T)$ under $A=a$.\n\nAssume the following structural equations:\n- Outcome equation (additive, no $A\\times S$ interaction):\n$$\nY(a,s)=\\beta_0+\\beta_A a-\\beta_S s+\\beta_M M_0,\\qquad \\beta_S>0,\\ \\beta_A\\ge 0.\n$$\n- Mediator dynamics: for each $a\\in\\{0,1\\}$, $S$ evolves according to the globally contracting linear ODE\n$$\n\\dot S(t)= -\\kappa\\big(S(t)-S^{(a)}\\big),\\qquad \\kappa>0,\n$$\nwith distinct fixed points $S^{(0)}=:S^{\\mathrm{high}}$ and $S^{(1)}=:S^{\\mathrm{low}}$ satisfying $S^{\\mathrm{low}}<S^{\\mathrm{high}}$. The unique solutions are\n$$\nS_T(a)=S^{(a)}+\\big(S_0-S^{(a)}\\big)e^{-\\kappa T}.\n$$\nHence, for every $S_0$,\n$$\n\\Delta S(S_0):=S_T(0)-S_T(1)=\\big(S^{\\mathrm{high}}-S^{\\mathrm{low}}\\big)\\big(1-e^{-\\kappa T}\\big)=:c>0,\\tag{1}\n$$\nwhich is uniform in $S_0$.\n\nDefine the pointwise total effect (TE) and natural indirect effect (NIE) through $S$:\n$$\n\\mathrm{TE}(S_0,M_0)=Y\\big(1,S_T(1)\\big)-Y\\big(0,S_T(0)\\big),\\quad\n\\mathrm{NIE}(S_0,M_0)=Y\\big(1,S_T(1)\\big)-Y\\big(1,S_T(0)\\big).\n$$\nBy the outcome equation,\n$$\n\\mathrm{TE}=\\beta_A+\\beta_S\\,\\Delta S(S_0),\\qquad \\mathrm{NIE}=\\beta_S\\,\\Delta S(S_0).\\tag{2}\n$$\nCombining (1)–(2), for all $S_0$ we have\n$$\n\\frac{\\mathrm{NIE}}{\\mathrm{TE}}=\\frac{\\beta_S c}{\\beta_A+\\beta_S c}.\n$$\nChoose any $\\theta\\in(0.3,0.6)$ and set $\\beta_A:=\\frac{1-\\theta}{\\theta}\\,\\beta_S\\,c\\ (\\ge 0)$. Then, for all $S_0$,\n$$\n\\mathrm{NIE}=\\theta\\,\\mathrm{TE},\n$$\nso, in particular, $\\mathrm{NIE}\\ge \\theta\\,\\mathrm{TE}$. This is uniform in $M_0$ because $M_0$ enters additively in $Y$ and cancels from both $\\mathrm{TE}$ and $\\mathrm{NIE}$.\n\nNow consider a pH-lowering adjunct given only with L13. Model its effect as shifting the L13 setpoint further downward by $\\Delta_{\\mathrm{pH}}>0$ while keeping the same contraction rate $\\kappa$:\n$$\nS^{(1,\\downarrow\\mathrm{pH})}:=S^{\\mathrm{low}}-\\Delta_{\\mathrm{pH}},\\qquad\nS_T^{\\downarrow\\mathrm{pH}}(1)=S^{(1,\\downarrow\\mathrm{pH})}+\\big(S_0-S^{(1,\\downarrow\\mathrm{pH})}\\big)e^{-\\kappa T}.\n$$\nA direct calculation gives\n$$\nS_T(1)-S_T^{\\downarrow\\mathrm{pH}}(1)=\\Delta_{\\mathrm{pH}}\\big(1-e^{-\\kappa T}\\big)=:\\delta>0,\n$$\nwhile $S_T^{\\downarrow\\mathrm{pH}}(0)=S_T(0)$ (the adjunct is only used with L13). Therefore\n$$\n\\Delta S^{\\downarrow\\mathrm{pH}}(S_0)=S_T^{\\downarrow\\mathrm{pH}}(0)-S_T^{\\downarrow\\mathrm{pH}}(1)=\\Delta S(S_0)+\\delta=c+\\delta,\\tag{3}\n$$\nfor all $S_0$. With the same $(\\beta_A,\\beta_S)$, the NIE share strictly increases because the map $x\\mapsto \\frac{\\beta_S x}{\\beta_A+\\beta_S x}$ is strictly increasing for $\\beta_A>0$ and (3) gives $x\\mapsto x+\\delta$:\n$$\n\\frac{\\mathrm{NIE}^{\\downarrow\\mathrm{pH}}}{\\mathrm{TE}^{\\downarrow\\mathrm{pH}}}\n=\\frac{\\beta_S(c+\\delta)}{\\beta_A+\\beta_S(c+\\delta)}\n>\\frac{\\beta_S c}{\\beta_A+\\beta_S c}=\\theta,\n$$\nagain uniformly in $M_0$.\n\nThus, there exist parameters and $\\theta\\in(0.3,0.6)$ such that for all $S_0$ the path-specific NIE through $S$ satisfies $\\mathrm{NIE}\\ge\\theta\\,\\mathrm{TE}$, and this NIE share strictly increases under a pH-lowering adjunct, uniformly in $M_0$. ∎"
  },
  {
    "statement": "There exist PK–PD settings in which Anti22’s efficacy and AE penalty depend only on Anti22 AUC through continuously differentiable, strictly increasing functions Φ and Ψ, such that for some λ_0>0 and all λ∈(0,λ_0], a regimen with pulsed Anti22 (duty cycle <1) and steady IL‑13 blockade satisfies J_λ(Dual_pulse)>J_λ(Dual_continuous) while achieving P(E75) within δ of Dual_continuous for arbitrary δ>0 by suitable pulse design.",
    "proof_markdown": "Proof. Fix a finite horizon $T>0$. Let Anti22 concentration $C_{22}(t)$ obey linear one-compartment PK with elimination rate $k>0$ and input $u(t)\\ge 0$ (Anti22 dosing rate): $\\dot C_{22}(t)=-kC_{22}(t)+u(t)$, $C_{22}(0)=0$. Define the Anti22 exposure over $[0,T]$ by\n$$A:=\\mathrm{AUC}(T)=\\int_0^T C_{22}(t)\\,dt.$$\nKeep IL-13 blockade steady (time-constant). Assume the mean efficacy and AE penalty depend only on Anti22 exposure:\n$$\\mathbb E[\\Delta\\mathrm{EASI}\\mid d]=\\Phi(A),\\qquad \\mathbb E[\\mathrm{AEs}\\mid d]=\\Psi(A),$$\nwith $\\Phi,\\Psi:\\mathbb R_+\\to\\mathbb R$ continuously differentiable and strictly increasing. The objective is\n$$J_\\lambda(d)=\\Phi(A)-\\lambda\\,\\Psi(A),\\qquad \\lambda\\ge 0.$$\nLet a continuous Anti22 add-on regimen (“Dual\\_continuous”) yield exposure $A_c>0$. For the EASI‑75 indicator, suppose there is regimen‑independent noise $Z$ with continuous CDF $F_Z$ and a fixed threshold $\\theta>0$ such that patient-level response satisfies $\\Delta\\mathrm{EASI}=\\Phi(A)+Z$. Then\n$$p(A):=\\mathbb P(E75\\mid A)=\\mathbb P(\\Phi(A)+Z\\ge\\theta)=1-F_Z\\big(\\theta-\\Phi(A)\\big).$$\nSince $F_Z$ is a CDF, it is nondecreasing and continuous; because $\\Phi$ is increasing, $A\\mapsto \\theta-\\Phi(A)$ is decreasing. Hence $A\\mapsto F_Z(\\theta-\\Phi(A))$ is nonincreasing, so $p(A)$ is nondecreasing and continuous.\n\nStep 1 (a uniform improvement window at small $\\lambda$). By continuity of $\\Phi'$ and $\\Psi'$ and $\\Phi'(A_c)>0$, there exists $\\varepsilon_0>0$ such that on $[A_c,A_c+\\varepsilon_0]$ we have $\\inf \\Phi'\\ge m:=\\tfrac12\\Phi'(A_c)>0$ and $M:=\\sup \\Psi'<\\infty$. Define $\\lambda_0:=m/(2M)$ (if $M=0$, any $\\lambda_0>0$ works). Then for any $\\lambda\\in(0,\\lambda_0]$ and any $a\\in[A_c,A_c+\\varepsilon_0]$,\n$$J_\\lambda'(a)=\\Phi'(a)-\\lambda\\Psi'(a)\\ge m-\\lambda M\\ge \\tfrac12 m>0.$$\nThus $J_\\lambda$ is strictly increasing on $[A_c,A_c+\\varepsilon_0]$ for all $\\lambda\\in(0,\\lambda_0]$. Consequently, for $\\varepsilon\\in(0,\\varepsilon_0]$,\n$$J_\\lambda(A_c+\\varepsilon)-J_\\lambda(A_c)=\\int_{A_c}^{A_c+\\varepsilon}J_\\lambda'(a)\\,da\\ \\ge\\ \\tfrac12 m\\,\\varepsilon\\ >\\ 0.$$\n\nStep 2 (arbitrarily small E75 deviation). By continuity of $p$ at $A_c$, for any $\\delta>0$ there exists $\\varepsilon(\\delta)\\in(0,\\varepsilon_0]$ such that\n$$|p(A_c+\\varepsilon)-p(A_c)|<\\delta\\quad\\text{whenever }\\varepsilon\\in(0,\\varepsilon(\\delta)].$$\nFix such $\\varepsilon\\in(0,\\varepsilon(\\delta)]$ and put $A_p:=A_c+\\varepsilon$.\n\nStep 3 (construct a pulsed Anti22 achieving $A_p$ with duty cycle $<1$). Fix any duty cycle $\\alpha\\in(0,1)$ and choose any nontrivial $\\alpha$-on/$1{-}\\alpha$-off input $u_0\\not\\equiv 0$ over $[0,T]$. In the linear PK system, the map $u\\mapsto A=\\int_0^T C_{22}(t;u)\\,dt$ is linear and positively homogeneous, so for $\\gamma:=A_p/A(u_0)>0$ the input $u_p:=\\gamma u_0$ is pulsed with duty cycle $\\alpha<1$ and produces exactly $\\mathrm{AUC}(T)=A_p$. Keep IL‑13 blockade steady; call the resulting regimen Dual\\_pulse.\n\nConclusion. For the constructed Dual\\_pulse and the baseline Dual\\_continuous, for all $\\lambda\\in(0,\\lambda_0]$,\n$$J_\\lambda(\\mathrm{Dual\\_pulse})=J_\\lambda(A_p)>J_\\lambda(A_c)=J_\\lambda(\\mathrm{Dual\\_continuous}),$$\nby Step 1, and\n$$\\big|\\mathbb P(E75\\mid\\mathrm{Dual\\_pulse})-\\mathbb P(E75\\mid\\mathrm{Dual\\_continuous})\\big|=|p(A_p)-p(A_c)|<\\delta,$$\nby Step 2. Since $\\delta>0$ is arbitrary and Dual\\_pulse has duty cycle $<1$, the statement follows. ∎"
  },
  {
    "statement": "There exists a data-generating process with two groups g ∈ {0,1} and baseline covariates Z = (L_0, M_0) such that, for every family of (possibly group-aware) dosing rules {δ_g(L_0, Z)} and for each group g,\n\nE[μ(L_0, δ_g(L_0, Z)) | g] ≤ sup_{c∈[0,1]} E[μ(L_0, c)],\n\nwith equality if and only if δ_g ≡ c* almost surely in that group, where c* attains sup_{c∈[0,1]} E[μ(L_0, c)]. Consequently,\n\nE[ΔEASI | {δ_g}] ≤ sup_{δ group-blind const} E[ΔEASI],\n\nwith strict inequality unless δ_g ≡ c* in every group. (No assumption on adverse events is needed; the claim is purely about efficacy.)",
    "proof_markdown": "We construct an instance and prove the claim groupwise.\n\nFeasible doses are m ∈ [0,1], and groups are g ∈ {0,1}. Conditional on g, let L_0 ∼ Unif[0,1], identically distributed across groups. Let Z = (L_0, M_0), where M_0 is arbitrary and may be used by dosing rules. Define efficacy\n\n$$\\mu(L,m) := A(m) + \\kappa\\,C(m)\\,L,$$\n\nwith parameters K > 0 and γ ∈ (0, \\tfrac14), where\n\n$$A(m) := -K\\,(m-\\tfrac12)^2, \\qquad C(m) := \\big(m-(\\tfrac12+\\gamma)\\big)_+^{\\,3}.$$ \n\nLet \\(\\overline C := \\sup_{m\\in[0,1]} C(m) = (\\tfrac12-\\gamma)^3 > 0\\), and choose \\(\\kappa \\in (0,\\, K\\gamma^2/\\overline C)\\).\n\n1) Best group-blind constant. For a constant dose c ∈ [0,1] and L ∼ Unif[0,1],\n\n$$F(c) := \\mathbb E[\\mu(L,c)] = A(c) + \\tfrac{\\kappa}{2} C(c).$$\n\nIf c ≤ \\(\\tfrac12+\\gamma\\), then C(c)=0 and F(c)=A(c) ≤ A(\\tfrac12), with equality only at c=\\(\\tfrac12\\). If c>\\(\\tfrac12+\\gamma\\), then\n\n$$A(\\tfrac12) - A(c) = K(c-\\tfrac12)^2 \\ge K\\gamma^2 > \\kappa\\,\\overline C \\ge \\kappa C(c),$$\n\nso\n\n$$A(\\tfrac12) - F(c) = \\big(A(\\tfrac12)-A(c)\\big) - \\tfrac{\\kappa}{2} C(c) > \\tfrac{\\kappa}{2} C(c) > 0.$$\n\nThus \\(\\sup_{c\\in[0,1]} F(c)\\) is attained uniquely at \\(c^* = \\tfrac12\\) with value \\(F(c^*) = A(\\tfrac12)\\).\n\n2) Arbitrary (possibly group-aware) dosing rules. Let an arbitrary measurable dosing rule be given, possibly group-aware and depending on all of Z, written \\(\\delta_g(L_0, M_0)\\in[0,1]\\). Fix g and abbreviate L = L_0 and m = \\delta_g(L_0, M_0). Define\n\n$$B^+ := \\{m > \\tfrac12+\\gamma\\}, \\quad B^- := \\{m < \\tfrac12-\\gamma\\}, \\quad s := \\mathbb P(B^+\\mid g),\\; t := \\mathbb P(B^-\\mid g).$$\n\nSince \\(A(\\tfrac12) - A(m) = K(m-\\tfrac12)^2 \\ge K\\gamma^2\\, \\mathbf 1_{B^+\\cup B^-}\\) and \\(C(m)=0\\) off \\(B^+\\),\n\n\\[\\begin{aligned}\n\\mathbb E[\\mu(L,m)\\mid g]\n&= \\mathbb E[A(m)\\mid g] + \\kappa\\, \\mathbb E[C(m)\\,L\\mid g] \\\\\n&\\le A(\\tfrac12) - K\\gamma^2\\, \\mathbb P(B^+\\cup B^-\\mid g) + \\kappa\\, \\overline C\\, \\mathbb E[\\mathbf 1_{B^+} L\\mid g] \\\\\n&\\le A(\\tfrac12) - K\\gamma^2 (s+t) + \\kappa\\, \\overline C\\, s \\\\\n&= A(\\tfrac12) - K\\gamma^2 t + (\\kappa\\, \\overline C - K\\gamma^2) s \\le A(\\tfrac12),\n\\end{aligned}\\]\n\nbecause \\(\\kappa\\,\\overline C < K\\gamma^2\\). Moreover, equality can hold only if \\(s=t=0\\), i.e., \\(m \\in [\\tfrac12-\\gamma,\\tfrac12+\\gamma]\\) almost surely, in which case \\(C(m)\\equiv 0\\) and\n\n$$\\mathbb E[\\mu(L,m)\\mid g] = \\mathbb E[A(m)\\mid g] \\le A(\\tfrac12),$$\n\nwith equality only when \\(m \\equiv \\tfrac12\\) almost surely (since \\(A(\\tfrac12)-A(m)=K(m-\\tfrac12)^2\\)). Hence, for every group g,\n\n$$\\mathbb E\\big[\\mu(L_0, \\delta_g(L_0,M_0)) \\mid g\\big] \\le A(\\tfrac12),$$\n\nwith equality if and only if \\(\\delta_g \\equiv \\tfrac12\\) almost surely in that group.\n\nAveraging over groups yields\n\n$$\\mathbb E\\big[\\mu(L_0, \\delta_g(L_0, M_0))\\big] \\le A(\\tfrac12) = \\sup_{c\\in[0,1]} F(c).$$\n\nBy construction, \\(\\mathbb E[\\Delta\\mathrm{EASI} \\mid \\{\\delta_g\\}] = \\mathbb E[\\mu(L_0, \\delta_g(L_0, M_0))]\\), so\n\n$$\\mathbb E[\\Delta\\mathrm{EASI} \\mid \\{\\delta_g\\}] \\le \\sup_{c\\in[0,1]} \\mathbb E[\\mu(L_0,c)] = \\sup_{\\delta\\,\\text{group-blind const}} \\mathbb E[\\Delta\\mathrm{EASI}],$$\n\nwith strict inequality unless \\(\\delta_g \\equiv c^* = \\tfrac12\\) in every group. This proves the tightened statement."
  },
  {
    "statement": "There exists a structural causal model with therapy $T\\in\\{D,\\mathrm{Dual}\\}$, mediator $M$ with baseline $M_0$, exposure $E$, and a threshold $\\tau_M$ such that:\n\n(i) the natural indirect effect of $T$ on $\\Delta$ via $M$ equals the total effect, i.e., $\\mathrm{NIE}_{T\\to\\Delta\\,\\mathrm{via}\\,M}=\\mathrm{TE}$; and\n\n(ii) for all $e_1>e_0$, the stratum-specific within-therapy exposure effect\n$$\\Delta_E(t;m):=\\mathbb E[\\Delta\\mid T{=}t,\\mathrm{do}(E{=}e_1),M_0{=}m]-\\mathbb E[\\Delta\\mid T{=}t,\\mathrm{do}(E{=}e_0),M_0{=}m]$$\nsatisfies $\\Delta_E(\\mathrm{Dual};m)<\\Delta_E(D;m)$ whenever $m\\ge\\tau_M$, with equality for $m<\\tau_M$.",
    "proof_markdown": "Define $T\\in\\{0,1\\}$ ($0\\equiv D$, $1\\equiv\\mathrm{Dual}$). Fix a threshold $\\tau_M\\in\\mathbb R$ and baseline mediator $M_0\\in\\mathbb R$. Consider the linear SCM (time indices suppressed):\n\\[\n\\begin{aligned}\nM&=M_0+\\big(\\beta-\\rho\\,\\mathbf 1_{\\{M_0\\ge\\tau_M\\}}\\,T\\big)\\,E\\ -\\ \\alpha\\,\\mathbf 1_{\\{M_0\\ge\\tau_M\\}}\\,T\\ +U_M,\\\\\n\\Delta&=\\gamma_0+c\\,E+d\\,M+U_\\Delta,\n\\end{aligned}\n\\]\nwith exogenous noises $U_M,U_\\Delta$ mean-zero and independent of $(T,M_0,E)$. Choose any parameters\n$$d>0,\\ \\beta>0,\\ \\rho>0,\\quad c,\\alpha\\in\\mathbb R\\text{ arbitrary}.$$ \n\n1) Stratum-specific within-therapy exposure effect and its selective reduction at high $M_0$. Under $\\mathrm{do}(E{=}e)$ and conditioning on $(T{=}t,M_0{=}m)$,\n\\[\n\\mathbb E[\\Delta\\mid T{=}t,\\mathrm{do}(E{=}e),M_0{=}m]=\\gamma_0+c\\,e+d\\Big(m+\\big(\\beta-\\rho\\,\\mathbf 1_{\\{m\\ge\\tau_M\\}}\\,t\\big)e-\\alpha\\,\\mathbf 1_{\\{m\\ge\\tau_M\\}}\\,t\\Big),\n\\]\nso for $e_1>e_0$,\n\\[\n\\Delta_E(t;m)=\\big(c+d(\\beta-\\rho\\,\\mathbf 1_{\\{m\\ge\\tau_M\\}}\\,t)\\big)\\,(e_1-e_0).\n\\]\nTherefore, for $m\\ge\\tau_M$,\n\\[\n\\Delta_E(1;m)=\\Delta_E(0;m)-d\\rho\\,(e_1-e_0)<\\Delta_E(0;m),\n\\]\nsince $d\\rho>0$ and $e_1-e_0>0$. For $m<\\tau_M$ the indicator vanishes, yielding $\\Delta_E(1;m)=\\Delta_E(0;m)=\\big(c+d\\beta\\big)(e_1-e_0)$.\n\n2) Natural indirect effect equals total effect. The outcome equation for $\\Delta$ contains $T$ only through $M$. Writing the structural potential outcome as $Y_{t,m,e}:=\\gamma_0+c\\,e+d\\,m+U_\\Delta$, we have $Y_{1,m,e}\\equiv Y_{0,m,e}$ for all $(m,e)$ (pointwise, for every realization of $U_\\Delta$). Hence the natural direct effect is\n\\[\n\\mathrm{NDE}=\\mathbb E\\big[Y_{1,M_{0,E,M_0},E}-Y_{0,M_{0,E,M_0},E}\\big]=0,\n\\]\nwhich implies $\\mathrm{TE}=\\mathrm{NIE}$ by the usual decomposition $\\mathrm{TE}=\\mathrm{NDE}+\\mathrm{NIE}$. This conclusion is independent of $\\alpha,c$ and of the distribution of $(E,M_0)$.\n\nCombining (1) and (2) proves the claim. Moreover, the argument shows the properties hold for any choice of parameters with $d>0,\\beta>0,\\rho>0$ and arbitrary $\\alpha,c$. ∎"
  }
]